Document:

exv10w24

 

[ * ] = Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.

Exhibit 10.24

LICENSE AND SUPPLY AGREEMENT

This License and Supply Agreement (this “Agreement”) is entered into as of February
28th, 2002 (the “Effective Date”) by and between Corixa Corporation, a Delaware
corporation having offices at 1124 Columbia Street, Suite 200, Seattle, Washington 98104, USA and
its Affiliates (“Corixa”), and Rhein Biotech N.V. having offices at Gaetano Martinolaan 95, 6229 GS
Maastricht, The Netherlands and its Affiliates, a Netherlands corporation (“Rhein”).

RECITALS

     A. Corixa owns intellectual property rights in an immunostimulatory material known as
Ribi.529TM adjuvant, which is a potentially useful component of vaccines to treat various human
disorders.

     B. Rhein is developing prophylactic and therapeutic vaccines for Hepatitis B and
desires to license from Corixa Ribi.529TM for use in such vaccines.

     C. Corixa is willing to provide Rhein access to Ribi.529TM adjuvant including the
supply thereof by Corixa and to grant Rhein a license under such intellectual property
rights in accordance with the terms and conditions set forth in this Agreement.

AGREEMENT

For good and valuable consideration, including the covenants and obligations expressed herein,
receipt of which is hereby acknowledged, intending to be legally bound, the parties hereto agree
as follows:

1. Definitions.

     1.1 “Affiliate” shall mean any business entity that Controls, is Controlled by, or is
under common Control with another corporation or business entity. The direct or indirect ownership
of at least fifty percent (50%) or, if smaller, the maximum allowed by applicable law, of the
voting securities or an interest in the assets, profits or earnings of a business entity shall be
deemed to constitute “Control” of the business entity.

     1.2 “cGMP” shall mean current good manufacturing practices as defined in the United
States Food and Drug Administration (FDA) rules and regulations, 21 CFR Part 211 for finished
pharmaceuticals, manufactured in the USA. “cGMP” shall also mean current good manufacturing
practices as defined in FDA’s “Guidance for Industry, Q7A Good Manufacturing Practice, Guidance for
Active Pharmaceutical Ingredients” for manufacturing of bulk Licensed Adjuvant in the USA.

     1.3 “Co-exclusive” shall mean that only the following entities shall have rights: On
the one hand, Rhein and its Affiliates and authorized Sublicensees, on the other hand
either (a) Corixa and its Affiliates or (b) a third party, including its Affiliates and
authorized Sublicensees, licensed by Corixa to use the Licensed Adjuvant in the Disease Field.

     1.4
“Confidential Information” shall have the meaning
assigned thereto in Section 13.1

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 1 of 24

 

     1.5 “Contract Manufacturer” shall have the meaning assigned thereto in Section 3.4.

     1.6 “Disease Field” shall mean the field of inducing an active, long-term prophylactic
or therapeutic immune response against Hepatitis B (including chronic status) in humans.

     1.7 “European Union” shall mean United Kingdom, Denmark, Sweden, Finland, Germany, The
Netherlands, Belgium, Luxembourg, France, Spain, Portugal, Italy, Greece, Austria, and Ireland, and
all other countries that become members at any time during the term of this Agreement.

     1.8 “Fill and Finish Manufacturer” shall have the meaning assigned thereto in Section
2.3(c).

     1.9 “Government Approval” shall mean any approvals, licenses, registrations or
authorizations of any Regulatory Authorities, necessary for the use, development, testing,
production, marketing, sale or distribution of the Licensed Product in a regulatory
jurisdiction.

     1.10 “Licensed Adjuvant” shall mean the aminoalkyl glucosamine phosphate
compound and compositions comprising such compound as described or claimed in the Licensed
Patents and including, without limitation, that compound identified as
2-[(R)-3-tetradecanolyloxytetradecanoyl-amino]ethyl2-deoxy-4-O-phosphono-3-O-[(R)-3tetradeca
noyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-b-D-glucopyranoside
triethylammonium salt and formulations of the same.

     1.11 “Licensed Patents” shall mean (a) the patents and patent applications set forth
in Appendix A hereto, (b) all continuations and divisionals of the foregoing, (c) all
patents issuing from any of the foregoing, and (d) all foregoing counterparts of any of the
foregoing.

     1.12 “Licensed Product” shall mean a prophylactic and/or therapeutic vaccine comprised
of antigen(s) owned or controlled by Rhein that also contains Licensed Adjuvant and that
potentially utilizes additional delivery or adjuvant technology, in pharmaceutical dosage forms
suitable for human use.

     1.13 “Manufacturing and Supply” shall mean the commercial manufacture, processing,
packing, holding, inkjet labeling, testing, storage, release and supply to Rhein or its designee of
Adjuvant in accord with the terms and conditions set forth in this
Agreement.

     1.14 “Net Sales” shall mean the gross amount invoiced by Rhein for the sale or other
disposition to an unaffiliated third party of Licensed Product, less the following deductions for
amounts actually incurred related to the sale or other disposition:

          (a) normal, customary trade discounts (including volume discounts), credits and rebates and
allowances and adjustments for rejections, recalls or returns; and

          (b) freight, insurance, sales, use, excise, value-added and similar taxes or duties imposed on
the sale and included in the gross amount invoiced.

     1.15 “Proposed Publication” shall have the meaning assigned thereto in Section 7.1.

     1.16 “Quality Plan” shall mean the mutually agreed upon quality plan that details
specific understandings related to product quality which is hereto attached as Appendix B
and incorporated herein by this reference, as such Quality Plan may be amended from time to time by
agreement of the parties in writing.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 2 of 24

 

     1.17 “Regulatory Authorities” shall mean those government agencies or authorities
responsible for the regulation of Licensed Product and/or Licensed Adjuvant (including without
limitation the manufacture, supply and sale thereof) in the Territory.

     1.18 “Specifications” shall mean those specifications set forth in Appendix C
with respect to pre-clinical and clinical supply of Licensed Adjuvant and the Quality Plan with
respect to commercial supply of Licensed Adjuvant.

     1.19 “Sublicensee” shall mean any permitted sublicensee of the license granted to
Rhein under this Agreement, except for the rights granted under Section 3.5, as further

described in Section 2.3.

     1.20 “Territory” shall mean worldwide.

2. License Grant.

     2.1 Subject to the terms and conditions of this Agreement, Corixa hereby grants to Rhein for
the term of this Agreement, unless earlier terminated in accordance with Section 16, a Co-exclusive
license, with the right to sublicense solely in accordance with Section 2.3, to research, use,
make, market, distribute and sell Licensed Products in the Territory for use solely in the Disease
Field. Such license grant does not permit (a) the manufacture by Rhein of Licensed Adjuvant save
for the right granted to Rhein under Section 3.5 or (b) the transfer by Rhein to any third party of
Licensed Adjuvant, other than as part of assembled Licensed Products or in accordance with Section
2.3, without the prior written approval of Corixa.

     2.2 The license granted in Section 2.1 is specific to the Disease Field. For the purpose of
clarification, Rhein shall have no right to include the Licensed Adjuvant in any product intended
for therapeutic or prophylactic use in any other disease field, whether such other product is
formulated as part of the Licensed Product or sold as in bundled package together with the Licensed
Product, unless a separate license for such other product and other disease field is expressly
granted in writing by Corixa to Rhein.

     2.3 Corixa hereby grants to Rhein for the term of this Agreement, unless earlier terminated in
accordance with Section 16, the right to sublicense the right to manufacture, use, market,
distribute and sell Licensed Product in the Territory in the Disease Field as follows:

          (a) Prior to the grant of a sublicense, Rhein shall notify Corixa in writing of the identity
of the intended Sublicensee, and Corixa shall have thirty (30) days to consent to the Sublicensee,
such consent not to be unreasonably withheld. If Corixa does not notify Rhein in writing within
such thirty (30) day period that Corixa does not consent to such Sublicensee, Corixa shall be
deemed to have consented. All sublicense agreements shall expressly bind the Sublicensee to the
terms of this Agreement and shall provide for the automatic assignment of the sublicense agreement
to Corixa if this Agreement is terminated. Rhein shall promptly furnish Corixa with a fully
executed copy of any sublicense agreement.

          (b) For the avoidance of doubt, either Rhein or its Sublicensee may manufacture, use, market
distribute and sell Licensed Product in any part of the Territory. In no event shall Rhein and its
Sublicensee exercise the license granted hereunder in the same country nor shall more than one
Sublicensee exercise the license granted hereunder in the same country. Furthermore, the right to
manufacture granted to Rhein under Section 3.5 is not sublicensable.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 3 of 24

 

          (c) For purposes of clarity, ‘manufacture’ includes the combining of the
Licensed Adjuvant and the antigen(s) to create the Licensed Product, but does not include the
manufacture of Licensed Adjuvant other than in accordance with Section 3.5. For further clarity,
the use of a third party (the “Fill and Finish Manufacturer”) solely for the combining of
the Licensed Adjuvant and the antigen(s) to create the Licensed Product, which will then be given
to Rhein or its Sublicensee for sale or other distribution, shall not be considered a
Sublicensee per se.

     2.4 Corixa hereby grants to Rhein for the term of this Agreement, unless earlier terminated in
accordance with Section 16, a non-exclusive license, without the right to sublicense, to use the
Licensed Adjuvant solely for preclinical and clinical research and
preclinical and clinical development in the Disease Field.

3. Supply of Licensed Adjuvant.

     3.1 Title to Licensed Adjuvant. Corixa shall retain all title and interest in and to any and
all Licensed Adjuvant provided by Corixa hereunder except as otherwise provided in this Agreement.

     3.2 Supply Price.

          (a) Corixa agrees to provide Rhein with quantities of Licensed Adjuvant reasonably required by
Rhein for use in Licensed Product. Corixa will provide clinical and commercial grade Licensed
Adjuvant on a bulk basis for incorporation into Licensed Product, at the following prices:

     (i) For pre-clinical and clinical grade (cGMP) Licensed Adjuvant, [ * ] per
milligram at [ * ] for Licensed Adjuvant in aqueous formulation and [ * ] per
milligram for lyophilized formulation and reference standard;

     (ii) For commercial grade (cGMP) Licensed Adjuvant, lyophilized formulation, [ * ] per gram for orders equal to or less than
[ * ] grams per year; [ * ] per
gram for orders greater than [ * ] grams and less than [ * ] grams per year; and [ * ] per gram for orders equal to or greater than [ * ] grams per year;

In all cases, the foregoing costs shall be plus shipping and insurance.

          (b) If Corixa’s manufacturing costs increase due to Rhein’s requirements for new or modified
Specifications or formulations of Licensed Adjuvant, the parties shall negotiate in good faith a
new pricing system. Corixa shall not be obligated to manufacture in accordance with any such new or
modified Specifications or formulations until the parties have agreed to a price.

          (c) Corixa shall have the right as from the first anniversary after the first commercial
supply of Licensed Adjuvant to annually increase its transfer prices in an amount not to exceed the
increase in the United States Consumer Price Index for all Urban Consumers (“CPI”) for the
immediately preceding twelve (12) month period over the index value at the beginning of such
period, provided that the permissible percentage increase in the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 4 of 24

 

transfer price on a given adjustment date shall not exceed three percent (3%) unless the increase
in the CPI for the immediately preceding twelve (12) month period exceeds ten percent (10%), in
which case for each percent the CPI for such period is over ten percent (10%) one additional
percent (1%) shall be added to the three percent (3%) cap.

     3.3 Forecasts. Within [ * ] after the Effective Date and on the first day of each quarter
thereafter, Rhein shall provide Corixa with a rolling forecast for the amount of Licensed Adjuvant
required for the [ * ] period that commences [ * ] following the date of the forecast. The
amounts for the [ * ] shall be [ * ]
. The amounts for the following [ * ] shall be [ * ] . The amounts forecasted for the [ * ] of the forecast (the “Ordered
Amount”) shall be automatically [ * ] firm and binding; [ * ] of the amounts forecasted for
the following [ * ] of the forecast shall be automatically [ * ] firm and binding; [ * ] and the amounts
forecasted for the [ * ] shall be non-binding.

          (a) The minimum of each Ordered Amount after Rhein has obtained a first registration in any
country in the Territory shall be [ * ] for the first and second year, [ * ] for the third year,
and [ * ] for the fourth year and thereafter.

          (b) Corixa shall fill each Ordered Amount within [ * ] from receipt of such order from Rhein;
provided, however, in the event a given order exceeds the requirements estimated in Rhein’s latest
[ * ] rolling forecast for the month in question, Corixa shall have up to [ * ] from receipt of
such order
to fill such excess requirements.

          (c) Notwithstanding any other provision of this Agreement, unless otherwise agreed to in
writing by Corixa, Corixa shall not be obligated to supply to Rhein in a given [ * ] more Licensed
Adjuvant than [ * ] above the amount estimated in Rhein’s latest [ * ] rolling forecast for the [
* ] in question, even if such quantity falls
within production capacities.

     3.4 Alternative Manufacturer. Rhein and Corixa agree that Corixa shall have the right in
connection with Corixa’s supply obligations hereunder to contract with one or more third parties
(the “Contract Manufacturer(s)”) for the manufacture and supply of the Licensed Adjuvant to
Rhein; provided, however, that (a) such Contract Manufacturer is reasonably acceptable to Rhein,
(b) Corixa shall cause each Contract Manufacturer to comply with the terms and conditions set forth
in this Agreement with respect to the manufacture and supply of such Licensed Adjuvant to Rhein,
and (c) Corixa shall remain fully responsible for the manufacture and supply of such Licensed
Adjuvant to Rhein.

     3.5 Inability to Supply.

          (a) In the event of Corixa’s or the Contract Manufacturer’s inability or failure to supply all
or any portion of Rhein’s requirements for Licensed Adjuvant [ * ] , other than as a result of
force majeure as
described in Section 17.9, Corixa hereby grants to Rhein a non-exclusive, non-assignable,
non-sublicensable royalty bearing right and license, to make or have made Licensed Adjuvant solely
for use in the production and manufacture of Licensed Product. If such event occurs, Corixa
shall transfer all relevant information and documentation to Rhein, including manuals and standard
operating procedures. All information provided by Corixa pursuant to this Section 3.5 shall be
Confidential Information and subject to the terms of Section 13 hereto. Rhein shall use
its best efforts to enter into any such manufacturing agreement on customary commercial

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 5 of 24

 

terms that will allow for termination upon Corixa’s ability to again supply Licensed Adjuvant.
Such right and license shall not be revoked until such time as Corixa is once again in a position
to meet its supply obligation under this Agreement, at which time Rhein’s agreement with any third
party manufacturer will be terminated early in accordance with the terms therein. To the extent
Rhein makes or has made Licensed Adjuvant pursuant to the foregoing right and
license, Rhein shall be obligated to pay to Corixa a manufacturing royalty equal to the royalty on
Net Sales set forth in Section 4.4.

          (b) In order to meet its obligations to Rhein under this Section 3, Corixa agrees to
maintain as a back-up supply of Licensed Adjuvant for Rhein in the amount set forth in Rhein’s then
current [ * ] forecast for the Licensed Adjuvant as set forth in Section 3.3 above.

     3.6 Conformance to Specifications. The Licensed Adjuvant supplied by Corixa or its
manufacturing designee hereunder shall conform at the time of delivery to Rhein to the applicable
Specifications. Rhein may test any Licensed Adjuvant delivered hereunder to determine conformance
of such Licensed Adjuvant with the applicable Specifications. If Rhein determines that such
Licensed Adjuvant does not meet such Specifications, Rhein shall within [ * ] of receipt of the
nonconforming Licensed Adjuvant notify Corixa in writing of such nonconformance, including test
results supporting Rhein’s determination. Corixa shall at
no charge to Rhein replace nonconforming Licensed Adjuvant with Licensed Adjuvant that meet such
Specifications. If Corixa disagrees with the alleged nonconformity of the Licensed
Adjuvant with the specifications, an independent laboratory, mutually agreed upon in writing by the
parties, shall analyze samples of the alleged nonconforming Licensed Adjuvant to
determine compliance with the Specification. Rhein and Corixa shall be bound by the
laboratory analysis of such Licensed Adjuvant. The cost incurred in connection with retaining
the independent laboratory shall be borne by Rhein if the Licensed Adjuvant in question is
found to conform to the Specifications and by Corixa if it is found to not conform to the
Specifications.

     3.7 Permitted Uses. Rhein shall use the Licensed Adjuvant supplied by Corixa hereunder only
for purposes of development, manufacture, marketing and sale of Licensed Product. Rhein shall use
the Licensed Adjuvant in compliance with this Agreement and with all applicable federal, state and
local laws and regulations. Rhein shall not transfer the Licensed Adjuvant or any related
information to any person who is not under the immediate and direct supervision of Rhein, except as
may otherwise expressly be provided in this Agreement.

     3.8 Access to Facilities. Corixa shall permit Rhein, Rhein bearing its own costs, and the
Regulatory Authorities and their respective agents and representatives reasonable access to the
facilities where the Manufacturing and Supply is being carried out at times mutually agreed to by
Corixa and Rhein.

     3.9 Shipping. Delivery shall be EXW Corixa’s facility, Hamilton, Montana lncoterms 2000. Title
to and risk for Licensed Adjuvant shall pass to Rhein upon delivery from said location.

     3.10 Maintenance of Records. Corixa shall keep or cause to be kept complete, accurate and
current records relating to all of its Manufacturing and Supply activities in accordance with all
applicable laws, cGMP and the requirements of the Regulatory Authorities in the United States and
European Union.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 6 of 24

 

3.11 Access to Records. Corixa shall provide Rhein with copies of all documentation
under Corixa’s control relating to its Manufacturing and Supply of Licensed Adjuvant to the extent
such documentation is required by any Regulatory Authority to be included in any Licensed Product
regulatory approval submission to the FDA or such other regulatory agency. Corixa hereby grants
Rhein and its Sublicensees the right to reference Corixa’s regulatory approvals, if any, for
Licensed Adjuvant and the drug master file for each Licensed Adjuvant on file with the FDA or any
other regulatory agency. Upon Rhein’s request, Corixa shall execute letters of authorization
evidencing Rhein’s and its Sublicensees’ reference rights as set forth above.

4. Payments and Reports.

     4.1 License Fee. As partial consideration for the rights and licenses granted hereunder,
Rhein shall pay Corixa a non-refundable, non-creditable license fee of [ * ] within ten (10) days
of execution of this Agreement.

     4.2 Milestones. As partial consideration for the rights and licenses granted hereunder, Rhein
shall pay Corixa the following non-refundable, non-creditable milestone payments:

          (a) [ * ] within thirty (30) days after trial AgB/RC-210-04 (the Supervax-trial) using
Licensed Product demonstrates statistically significant clinical benefit in terms of efficacy, as
defined as the primary endpoint in the efficacy evaluable population in Protocol CCHB001-01 based
on the clinical study database that has been locked at Corixa.

          (b) [ * ] within thirty (30) days following the first Licensed Product product registration
anywhere in the Territory.

     4.3 Annual Maintenance Fees; Minimum Annual Royalty. Rhein shall pay Corixa an annual license
fee on each anniversary of the Effective Date until commercial launch of the Licensed Product,
after which such fee shall be paid as the minimum annual royalty payment, in accordance with the
following schedule: [ * ] on the first anniversary of the Effective Date; [ * ] on the second
anniversary of the Effective Date; and [ * ] on the third and subsequent anniversaries of the
Effective Date. All such annual maintenance fees or minimal annual royalties, as applicable, shall
be guaranteed, non-
refundable and non-creditable, except, however, that after commercial launch of the Licensed
Product, the minimal annual royalty payments shall be credited against the royalty payment
paid to Corixa in the calendar year of such minimum annual royalty payment. All payments
made under this Section 4.3 shall be in accordance with the schedule set forth in Section 4.5
below.

     4.4 Royalties. As partial consideration for the rights and licenses granted hereunder, Rhein
shall pay Corixa royalty payments in accordance with the following rates on annual Net Sales made
by Rhein or its sublicensee of each Licensed Product, commencing with the first commercial sale of
the Licensed Product anywhere in the Territory: [ * ] on Net Sales in the United States or the
European Union, and [ * ] on Net Sales in the rest of the world.

     4.5 Payment Schedule. Royalties shall be calculated on a semi-annual basis, specifically, the
periods January 1 through June 30 and July 1 through December 31, (“Semi-Annual Period”) and shall
be due and payable within forty-five (45) days after the end of such

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 7 of 24

 

Semi-Annual Period, commencing upon the completion of the first Semi-Annual Period during
which the first commercial sale occurs.

     4.6 Payment Reports. Forty-five (45) days following the end of each Semi-Annual Period, Rhein
shall furnish to Corixa a written report that includes (a) the identity of the countries in which
sales of Licensed Product have been made and (b) the Net Sales of each Licensed Product and the
number thereof sold in each such country. Such reports shall be due together with the royalty
payments under Section 4.4 subsequent to launch of the Licensed Products. Such reports shall be
made whether or not Rhein has engaged in any sales of Licensed Product during the Semi-Annual
Period. All information provided by Rhein pursuant to this Section 4.6 shall be Confidential
Information and subject to the terms of Section 13 hereto.

     4.7 Audits. Rhein shall keep, and shall cause its Sublicensee to keep, full, complete and
accurate records and accounts of Net Sales of each Licensed Product in sufficient detail to enable
the royalties payable to Corixa to be determined. Upon reasonable notice to Rhein,
Corixa shall have the right to have an independent certified public accountant audit Rhein’s
and its Sublicensee’s records pertaining to Licensed Products during normal business hours to
verify the royalties payable pursuant to this Agreement; provided, however that (a) such audit
shall not take place more frequently than once a year, and (b) shall not cover such records for
more than the preceding three (3) years. Such audits shall be at Corixa’s expense unless such
audit determines that Rhein has paid Corixa less than ninety-five percent (95%) of the amount
determined to be due for a given time period, in which case such audit shall be at Rhein’s expense
and Rhein shall pay to Corixa the cost of such audit and any shortfall in payments due
to Corixa within thirty (30) days following Corixa’s invoice to Rhein therefor. Rhein shall
preserve and maintain all such records and accounts required for audit for a period of three
(3) years after the calendar year to which such records and accounts apply.

     4.8 Payment Instructions. All payments due hereunder shall be made in U.S. Dollars by wire
transfer of immediately available funds to the following account:

Account No. [ * ]

Bank: [ * ]

ABA Code: [ * ]

or to such other account as Corixa may designate from time to time.

     4.9 Past Due Amounts. Any past due payments under this Agreement shall accrue interest until
paid at [ * ] per annum, or the maximum rate permitted by law, whichever is less.

     4.10 Foreign Currency. Currency conversions to U.S. Dollars shall be calculated using an
average rate of exchange, which rate of exchange shall be computed by adding the rate of exchange
quoted under Foreign Exchange in the Wall Street Journal as of the end of the current quarter to
the rate as of the end of the prior month and dividing by 2.

     4.11 Withholding Tax. Rhein shall be entitled to deduct from amounts otherwise due and
payable hereunder, any withholding taxes, value-added taxes or other taxes, levies or charges with
respect to amounts payable hereunder, other than United States taxes and/or
taxes imposed on or measured by net income, payable by Rhein, or any taxes required to be
withheld by Rhein, to the extent Rhein pays to the appropriate governmental authority on behalf of
Corixa such taxes, levies or charges. Rhein shall use reasonable efforts to minimize any
such taxes, levies or charges required to be withheld on behalf of Corixa by Rhein. Rhein

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 8 of 24

 

promptly shall deliver to Corixa proof of payment of all such taxes, levies and other charges,
together with copies of all communications from or with such governmental authority with
respect thereto. Rhein shall cooperate in full with Corixa regarding the characterization of
payments so that it may take advantage of any and all benefits under any treaties or in efforts
required by Corixa to receive any reimbursement or refund of amounts so paid or withheld.

5. Performance Obligations.

     5.1 Commercial Development. Rhein shall use its best commercial efforts to meet the
development schedule attached hereto as Appendix D. Rhein shall at all times keep Corixa
generally informed of Rhein’s updated development plans, which Rhein shall provide to Corixa
in writing semi-annually, for each Licensed Product, including Rhein’s planned timing for Licensed
Product commercial launch dates on a country-by-country basis. All dates and other information
provided by Rhein in such plan shall be used for planning purposes only, and shall be subject to
reasonable modification by Rhein based on its actual progress in the development process. Corixa
and Rhein shall meet annually regarding Rhein’s efforts under this Agreement. Not more than two
representatives from each Rhein and Corixa shall attend such meeting, which may take place either in person in a location equidistant from each party’s facilities or via
teleconference. At least [ * ] prior to each such meeting, Rhein shall submit an annual written
report to Corixa that summarizes Rhein’s efforts toward development and commercialization of
Licensed Products.

     5.2 Marketing Documentation. At all times during the term of this Agreement, Rhein agrees to
furnish reasonably promptly to Corixa all documentation and data that is or may hereafter be in
Rhein’s possession relating to Rhein’s marketing of Licensed Products, including, but not limited
to, marketing support data. All such information and data shall be Confidential lnformation subject
to Section 13 hereof.

     5.3 Training. Corixa shall provide a total of [ * ] of training and technical support on
formulation, including but not limited to liquid and lyophilized, and analysis at Corixa’s Montana
facility. Rhein shall bear all of its costs related thereto, including but not limited to travel
expenses. Should Rhein require training in excess of [ * ] , Rhein shall reimburse Corixa for FTE
costs at Corixa’s then current rate. All formulation and analysis information and know-how provided
by Corixa shall be Confidential lnformation pursuant to Section 13.

6. Governmental Approvals.

     6.1 Rhein shall be responsible at Rhein’s expense for obtaining all Government Approvals in
any country where Licensed Product shall be manufactured or sold or otherwise distributed. Corixa
agrees to provide Rhein, at Rhein’s expense, with any assistance reasonably requested by Rhein, in
obtaining such Governmental Approvals.

     6.2 Within sixty (60) days following receipt by Rhein, Rhein shall promptly provide Corixa
with notice of all Government Approvals received by Rhein regarding Licensed Product.

7. Publications.

     7.1 In General. Rhein shall not publish or present, orally or in writing, including without
limitation at symposia, national or regional professional meetings, or to publish in journals or
other publications, any Confidential lnformation derived from or in any way relating to any aspect
of the Licensed Adjuvant, whether separately or as part of Licensed Product, or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 9 of 24

 

Licensed Patents, including, but not limited to, the development or manufacture of the
Licensed Adjuvant, whether separately or as part of Licensed Product (the “Proposed
Publication”), without providing Corixa the opportunity for prior review. The Proposed
Publication will be submitted to Corixa at least [ * ] prior to the date on which it is to be
submitted or disclosed to any person or entity not a party to this Agreement. During the
[ * ] period, Corixa will review the Proposed Publication for accuracy, disclosure of patentable
material or disclosure of its Confidential Information. If, in Corixa’s sole opinion, a Proposed
Publication contains patentable material, Corixa will so notify Rhein before the expiration of the
[ * ] review period. After such notice, Corixa may delay publishing
for a period of up to [ * ] , to permit filing of appropriate patent applications. Corixa shall
have the right to remove its Confidential Information from any Proposed Publication.

     7.2 Public Announcements.

          (a) Within 7 days of the execution of this Agreement, parties agree to issue a joint press
release on the same date. This press release must receive the prior written approval
of each party prior to issuance, which approval shall not be unreasonably withheld.

          (b) During the term of this Agreement, the parties agree to consult with each other before
issuing any press release or making any public statement based on new or previously undisclosed
information with respect to this Agreement or any other transaction contemplated herein and, except
as may be required by applicable law or any listing agreement with any national securities
exchange, shall not issue any such press release or make any
such public statement prior to obtaining the written consent of the other party.

8. Ownership of Inventions.

lnventorship of all inventions or discoveries shall be determined in accordance with the patent
laws of the United States. Rhein hereby assigns to Corixa all of its right, title and interest in
and to any and all inventions or discoveries that are improvements, including new uses, of or to
the Licensed Adjuvant or any other subject matter disclosed in the Licensed Patents. All such
improvements shall be included within the license granted to Rhein hereunder.

9. Representations and Warranties.

     9.1 Nontransfer. Rhein represents and warrants that it will not transfer the Licensed
Adjuvant, other than as part of the Licensed Products, to any third party without the prior written
consent of Corixa, save for Rhein’s transfer of Licensed Adjuvant to its Sublicensee or Fill and
Finish Manufacturer, if any, solely to allow such Sublicensee or Fill and Finish Manufacturer to
exercise its right to manufacture Licensed Product as stipulated in Section 2.3.

     9.2 Compliance with Law. Rhein warrants that all Licensed Products manufactured and/or sold
or distributed by Rhein will be manufactured, sold and distributed in accordance with all
applicable laws, rules and regulations of the country of manufacture, sale or distribution of such
Licensed Products.

     9.3 No Conflict. Each party hereby represents and warrants that it is authorized to enter
into this Agreement and that this Agreement does not create a conflict with any other right or
obligation provided under any other agreement or obligation that party has with any third party.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 10 of 24

 

     9.4 Infringement. Corixa represents and warrants that as of the Effective Date, to Corixa’s
actual knowledge, the manufacture, use, offer for sale, and sale of the Licensed Adjuvant does not
infringe or involve the misappropriation of any intellectual property of any third party.

10. Indemnification.

     10.1 Rhein hereby agrees to indemnify, defend and hold harmless Corixa, its Affiliates and
their officers, agents and employees from and against any and all claims, actions, proceedings,
liabilities or losses, including reasonable legal expenses and costs, including attorney fees
(collectively, “Losses”), that arise from (a) any material breach of this Agreement,
including a breach of any representation, warranty or covenant made by Rhein hereunder, by Rhein or
its Sublicensee(s), (b) the negligence or willful misconduct of Rhein, its Affiliates or
Sublicensee(s) and the employees, agents and contractors thereof, (c) any manufacturing of Licensed
Adjuvant or Licensed Product, (d) the Licensed Product infringing upon or violating
any third party’s patent or other proprietary rights, except for infringements caused by the
Licensed Adjuvant as warranted under Section 9.4, or (e) any handling, possession, use, marketing,
distribution or sales of Licensed Product; provided, however, that Rhein shall have
no obligation to indemnify Corixa to the extent that such Losses are the result of Corixa’s gross
negligence or willful misconduct.

     10.2 Corixa hereby agrees to indemnify, defend and hold harmless Rhein from and against any
and all losses arising from or based on Corixa’s gross negligence or willful misconduct.

     10.3 Insurance. Rhein shall obtain and maintain in effect during the term of this Agreement
and for five (5) year thereafter, with financially strong insurance carriers (AM Best Rating of “A”
V or higher), commercial general liability insurance covering bodily injury and property damage
necessary to meet its liability obligations under this Agreement or amounts comparable to other
companies of the same size and having the same business as Rhein. Rhein shall provide a statement
to Corixa in which Rhein identifies its insurer and warrants that its coverage is sufficient to
meet its obligations set forth herein. The insurance limits will be increased as a function of
increasing sales levels. There shall be a thirty (30) day notice of cancellation with respect to
the insurance coverage, and Corixa shall be notified in the event of any material change directly
affecting Corixa in the insurance contract or coverages afforded. Rhein shall be solely responsible
for the payment of any deductible.

11. Limitation of Liability.

IN NO EVENT WILL EITHER PARTY HERETO BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR
INDIRECT DAMAGES SUFFERED BY THE OTHER PARTY ARISING IN ANY WAY OUT OF THIS AGREEMENT, HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

12. Disclaimer of Warranties.

          ALL LICENSED ADJUVANT ARE LICENSED AND SUPPLIED HEREUNDER “AS IS,” AND CORIXA HEREBY DISCLAIMS ANY
AND ALL REPRESENTATIONS AND WARRANTIES WITH REGARD TO THE LICENSED ADJUVANT, THE LICENSED PRODUCTS
AND THE LICENSED PATENTS, EXPRESS OR IMPLIED, AND SPECIFICALLY DISCLAIMS ANY OTHER EXPRESS OR
IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 11 of 24

 

OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE AND ANY OTHER STATUTORY WARRANTIES OR
ANY WARRANTY OF PATENTABILITY OR NONINFRINGEMENT.

13. Confidentiality.

     13.1 Confidential Information. “Confidential Information” shall mean any proprietary
information that is specifically designated as such and that is disclosed by either party to the
other in any form in connection with this Agreement. For the term of this Agreement and five
(5) years from the date of expiration or termination, each party (a) shall treat as confidential
all Confidential lnformation provided by the other party, (b) shall not use such Confidential
lnformation except as expressly permitted under the terms of this Agreement or otherwise authorized
in writing by the disclosing party, (c) shall implement reasonable procedures to
prohibit the disclosure, unauthorized duplication, misuse or removal of such Confidential
Information, and (d) shall not disclose such Confidential lnformation to any third party. Without
limiting the foregoing, each of the parties shall use at least the same procedures and degree of
care to prevent the disclosure of Confidential lnformation as it uses to prevent the disclosure of
its own confidential information of like importance, and shall in any event use no less than
reasonable procedures and a reasonable degree of care.

     13.2 Exceptions. Notwithstanding the above, neither party shall have liability to the other
with regard to any Confidential lnformation that:

          (a) was generally known and available to the public domain at the time it was disclosed, or
becomes generally known and available to the public domain through no fault of
the receiver;

          (b) was known to the receiver at the time of disclosure as shown by the written records in
existence at the time of disclosure;

          (c) is disclosed with the prior written approval of the disclosing party;

          (d) becomes known to the receiving party from a source other than the disclosing party without
breach of this Agreement by the receiving party and in a manner which is otherwise not in violation
of the disclosing party’s rights; or

          (e) is disclosed pursuant to the order or requirement of a court, administrative agency, or
other governmental body; provided, that the receiving party shall provide reasonable advance notice
to enable the disclosing party to seek a protective order or otherwise prevent such disclosure.

14. Infringement.

     14.1 If any patent infringement action is brought against Rhein or any of suppliers,
distributors, or customers because of actual or anticipated manufacture, use or sale of a Licensed
Product and such action claims that such manufacture, use, or sale infringes the intellectual
property rights of a third party, Rhein shall promptly notify Corixa and send Corixa copies of all
papers that have been served. Corixa shall have the first right to control the defense of such
action at its own expense, provided that such first right to control will be limited to the
Licensed Patents covering the Licensed Adjuvant, and Rhein shall at all times cooperate with Corixa
and continue to pay royalties on any Net Sales of Licensed Product during the pendency of such
action and any appeals.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 12 of 24

 

     14.2 If Corixa fails to defend such infringement action after being notified by Rhein, Rhein
shall have the right, but not the obligation, to defend the action itself. If Rhein does undertake
such defense, Corixa shall cooperate with Rhein and shall be entitled to select
legal counsel of its choice. All costs and expenses incurred by Rhein, including settlement
costs, damages assessed against Rhein, and reasonable attorney fees, shall be paid by Rhein.

     14.3 Neither party shall be permitted to settle a legal action without the prior written
consent of the other party, which consent shall not be unreasonably withheld; provided, however,
that Corixa shall have the right to settle, without Rhein’s consent, any legal action, or part
thereof, that relates solely to the Licensed Adjuvant.

15. Enforcement

     15.1 If during the term of this Agreement, either party becomes aware of a third party
infringement or threatened infringement of any Licensed Patents, the following provisions shall
apply:

          (a) The party having such knowledge shall promptly give notice to the other party, with all
available details.

          (b) Corixa shall have the right, but not the obligation, to bring suit in its name at its own
expense to restrain such infringement and to recover profits and damages. Rhein agrees at Corixa’s
request to be joined as a party plaintiff and to cooperate in the prosecution thereof, as is
reasonably necessary, at Corixa’s expense. If Corixa decides to undertake such suit, then Corixa
shall have the sole right to control prosecution and shall retain all proceeds therefrom.

          (c) If Corixa fails to take action within [ * ] after becoming aware of such infringement, in
the first instance or by notice from Rhein, then Rhein, at any time prior to Corixa thereafter
filing an action and solely to the extent such infringement or threatened infringement involves a
vaccine product for use in the Disease Field, shall have the right, but not the obligation to take
such action in its own name. Corixa shall cooperate with Rhein, at Rhein’s expense, as is
reasonably necessary in any such action brought by Rhein. If Rhein brings legal action, Rhein shall
have the sole right to control prosecution and shall retain all proceeds therefrom.

          (d) In the event of a cooperative legal action involving both Corixa and Rhein and a monetary
recovery in connection with such action is obtained, such recovery shall be applied in the
following priority: (i) to reimburse Corixa and Rhein by proportion and up to the extent of their
actual out-of-pocket expenses (including reasonable attorney fees) in
prosecuting such infringement, (ii) to be shared by the proportion and up to the extent of any
damages established, including but not limited to Rhein’s lost profits and Corixa’s lost royalties,
and (iii) the balance, if any, to be shared one-half by Corixa and one-half by Rhein.

16. Term and Termination.

     16.1 Term. The term of this Agreement shall be for a period of fifteen (15) years from the
Effective Date.

     16.2 Termination by Agreement. This Agreement may be earlier terminated by either party upon
mutual written agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 13 of 24

 

     16.3 Termination for Breach. Upon any material breach of this Agreement by either party, the
non-breaching party may terminate this Agreement upon thirty (30) days written
notice to the breaching party. The notice shall become effective at the end of the thirty (30) day
period unless the breaching party shall cure such breach within such period. For purposes of
this Agreement, Material breach shall be deemed to include, but not be limited to, (a) the sale of
Licensed Product outside of the Disease Field, (b) distribution of Licensed Adjuvant other than as
allowed under this Agreement, (c) failure to pay the royalties payable under Section 4, (d) failure
to comply with the publication obligations specifically related to Licensed Adjuvant and/or
Licensed Patents under Section 7.1, and (e) failure to comply with the insurance requirements under
Section 10.3.

     16.4 Bankruptcy. Either party may terminate this Agreement by giving thirty (30) days written
notice to the other party if such other party (a) files a petition of bankruptcy or has any such
petition filed against such other party; (b) goes into compulsory liquidation; (c) has its business
placed in the possession of a receiver, a government or a government agency; (d) makes an
assignment for the benefit of creditors; or (e) is subject to a dissolution or winding up.

     16.5 Effects of Termination. Neither expiration nor termination shall relieve either party of
its obligations under Sections 4.6 through 4.10, 7, 8, 9 through 14 or 17. Further,
Rhein shall make all reports and payments as are required for the final quarter. Upon
expiration or termination hereof, at Corixa’s option, Rhein shall return or destroy, and certify
destruction of, any Licensed Adjuvant in Rhein’s possession or control.

17. General Provisions.

     17.1 Independent Contractors. Corixa and Rhein shall be independent contractors and shall not
be deemed to be partners, joint venturers or each other’s agents, and neither party shall have the
right to act on behalf of the other except as is expressly set forth in this Agreement.

     17.2 Entire Agreement; Amendment. This Agreement sets forth the entire agreement and
understanding between the parties and supersedes all previous agreements, promises,
representations, understandings, and negotiations, whether written or oral between the parties with
respect to the subject matter hereof. There shall be no amendments or modifications to this
Agreement, except by a written document signed by both parties.

     17.3 Assignment. This Agreement shall be binding upon and shall inure to the benefit of any
successor or successors of Corixa and Rhein by reorganization, merger, consolidation or otherwise,
and any assignee that has acquired all of substantially all of the business and properties of
either. Corixa and Rhein shall not otherwise assign their rights and obligations hereunder unless
having obtained the prior written consent of the other party hereto, which consent will not be
unreasonably withheld or delayed.

     17.4 Governing Law; Injunctive Relief.

          (a) This Agreement shall be construed and enforced in accordance with the laws of the state of
Washington, without giving effect to its or any other jurisdiction’s principles
of conflicts of law.

          (b) Corixa shall have the right to such injunctive relief or other legal or equitable relief
as is reasonable to ensure that Rhein does not transfer the Licensed Adjuvant to a third party,
except as allowed under this Agreement, without Corixa’s prior written consent.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 14 of 24

 

     17.5 Dispute Resolution. Any dispute or claim arising out of or in connection with this
Agreement shall be resolved as follows: (a) for a period of thirty (30) days after a dispute arises
the respective chief executive officers of the parties or their designees shall negotiate in good
faith in an effort to resolve the dispute, and (b) if the dispute has not been resolved at the
close of such thirty (30) day period, the matter will be finally settled by binding arbitration
under the Rules of Arbitration of the American Arbitration Association, by one arbitrator appointed
in accordance with said rules; provided, that if the parties cannot agree on the arbitrator, the
dispute shall be resolved by a panel of three arbitrators, wherein each party shall appoint one
arbitrator and those arbitrators shall in turn jointly appoint the third arbitrator. The language
of the arbitration shall be in English. Judgment on an award rendered by an arbitrator or
arbitrators may be entered in any court having jurisdiction. Notwithstanding the foregoing,
the parties may apply to any court of competent jurisdiction for preliminary or interim equitable
relief without breach of this arbitration provision. Such arbitration shall be held in Seattle,
Washington.

     17.6 Severability. If any provision of this Agreement is finally held to be invalid, illegal
or unenforceable by a court of competent jurisdiction, the validity, legality and enforceability of
the remaining provisions shall not be affected or impaired in any way.

     17.7 Waiver. Any delay or failure in enforcing a party’s rights under this Agreement or any
waiver as to a particular default or other matter shall not constitute a waiver of a party’s right
to the future enforcement of its rights under this Agreement.

     17.8 Trademark Ownership and Usage.

          (a) Rhein, at its expense, shall be responsible for the selection, registration and
maintenance of all trademarks that it employs in connection with Licensed Product and
shall own and/or control such trademarks. Nothing in this Agreement shall be construed as a grant
of rights, by license or otherwise, to Corixa to use such trademarks for any purpose.

          (b) Rhein shall, where legally permitted and at Corixa’s request, include in the packaging of
Licensed Products wording that is mutually agreeable to the parties (Rhein’s agreement not to be
unreasonably withheld), to indicate Corixa’s licensor status in relation to Licensed Products.
Notwithstanding the foregoing, if Rhein sells, offers for sale, imports or manufactures Licensed
Product in the United States, Rhein shall include the U.S. patent numbers that have been issued or
published as applications on the packaging, which shall be reviewed and approved by Corixa, such
approval shall not be unreasonably withheld, prior to use.

          (c) In marketing Licensed Products, Rhein will clearly label such Licensed Products sold by
Rhein in compliance with the law and Rhein shall procure from its Sublicensee hereunder an
agreement to clearly label such Licensed Products in compliance with the law. In marketing Licensed
Products, Rhein’s labeling of such Licensed Products shall include Corixa’s trademarks, “Ribi.529TM
adjuvant” and “Powered by CorixaTM” in a manner that the parties agree is commercially reasonable
and Rhein shall require its Sublicensee to so label Licensed Products marketed by such Sublicensee.

     17.9 Notice. Any notice required or permitted by this Agreement to be given to either party
shall be in writing and shall be deemed given when delivered personally, by confirmed telecopy to a
fax number designated in writing by the party to whom notice is given, or by registered, recorded
or certified mail, return receipt requested, and addressed to the party to whom such notice is
directed, at:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 15 of 24

 

If to Corixa:

Corixa Corporation

1124 Columbia Street, Suite 200

Seattle, Washington 98104, USA

Attention: Senior Vice President, Chief Operating Officer

Copy: General Counsel

[ * ]

If to Rhein:

Rhein Biotech N.V.

Gaetano Martinolaan 95

6229 GS Maastricht, The Netherlands

Attention: President and CEO

Copy: VP Legal Affairs

[ * ]

or at such other address or telecopy number as such party to whom notice is directed may
designate to the other party in writing.

     17.10 Force Majeure. If the performance of this Agreement or any obligations hereunder is
prevented, restricted or interfered with by reason of fire or other casualty or accident, strikes
or labor disputes, war or other violence, any law, order, proclamation, ordinance, demand or
requirement of any government agency, or any other act or condition beyond the control of the
parties hereto, the party so affected, upon giving prompt notice to the other party shall be
excused from such performance (other than the obligation to pay money) during such prevention,
restriction or interference.

     17.11 Headings. The section headings appearing in this Agreement are inserted only as a
matter of convenience and in no way define, limit, construe or describe the scope or extent of such
section or in any way affect such section.

     17.12 Counterparts. This Agreement may be signed in counterparts, each of which shall be
deemed an original and all of which together shall constitute one instrument.

{Signature page follows}

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 16 of 24

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
above written.

	 	 	 	 	 
	 

	 	CORIXA CORPORATION	 	 
	 

	 	1124 Columbia Street, Suite 200	 	 
	 

	 	Seattle, Washington 98104, USA	 	 
	 
	 	 	 	 
	 

	 	/s/ Steven Gillis
 

	 	 
	 

	 	Steven Gillis, Ph.D.	 	 
	 

	 	Chairman and Chief Executive Officer	 	 
	 
	 	 	 	 
	 

	 	RHEIN BIOTECH N.V.	 	 
	 

	 	Gaetano 95 he Netherlands	 	 
	 

	 	6229 GS Maastrieht, The Netherlands	 	 
	 
	 	 	 	 
	 

	 	/s/ T. Y. Thio	 	 
	 

	 	 	 	 
	 

	 	Dr. T. Y. Thio	 	 
	 

	 	Sr. Vice President Business Development	 	 
	 
	 	 	 	 
	 

	 	/s/ C.P.E. Moonen	 	 
	 

	 	 	 	 
	 

	 	Vice President Legal Affairs	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 17 of 24

 

APPENDIX A

Licensed Patents

	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	 	 	 
	Number	 	TITLE	 	Country	 	Serial No/Filing Date	 	Status
	[ * ]

	 	AMINOALKYL

GLUCOSAMINE

PHOSPHATE COMPOUNDS

AND THEIR USE AS

ADJUVANTS AND

IMMUNOEFFECTORS
	 	U.S.
	 	[ * ]

Filed: 5/8/97
	 	Issued 9/5/00 as
Patent No. 6,113,918
(Expires 5/8/17)
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	U.S.
	 	[ * ]

Filed: 5/7/98
	 	Notice of Allowance
dated 10/18/99—Issue
Fee paid 1/18/00
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	AMINOALKYL

GLUCOSAMIDE

PHOSPHAT COMPOUNDS

AND THEIR USE AS

ADJUVANTS AND

IMMODEPRESSORS
	 	U.S.
	 	[ * ]

Filed: 11/12/99
	 	Issued 10/16/2001 as
Patent No. 6,303,347
(Expires 5/8/17)
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	U.S.
	 	[ * ]
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	PCT
	 	[ * ]
	 	Converted
	 

	 	 	 	 	 	Filed 5/7/98
	 	Publication No. WO
9850399; published
10/12/98
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	ARIPO
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Australia
	 	[ * ]

Filed 5/7/98
	 	Allowed
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Brazil
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Canada
	 	[ * ]

Filed 5/7/98
	 	Pending
Request Exam May 2003
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	China
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Europe
	 	[ * ]

Filed 5/7/98
	 	Pending
EP Publication No.
983286
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Hong Kong
	 	[ * ]

Filed 5/7/98
	 	EP Publication No.
983286

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 18 of 24

 

	 	 	 	 	 	 	 	 	 
	Docket	 	 	 	 	 	 	 	 
	Number	 	TITLE	 	Country	 	Serial No/Filing Date	 	Status
	[ * ]

	 	“
	 	Hungary
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Indonesia
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Israel
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Japan
	 	[ * ]

Filed 5/7/98
	 	Pending
Request Exam May 2005
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	North Korea
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	South Korea
	 	[ * ]

Filed 5/7/98
	 	Pending
Request Exam May 2005
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Mexico
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	New Zealand
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	OAPI
	 	[ * ]

Filed 5/7/98
	 	Granted 6/12/2000 as
Patent No. 11214
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Poland
	 	[ * ]

Filed 5/7/98
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	PCT
	 	[ * ]

Filed: 11/13/00
	 	Published 5/17/2001
Publication No. WO
01/34617
30th Mo.
Conversion 5/12/2002
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Argentina
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Colombia
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Gulf Cooperation

Council
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Malaysia
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Philippines
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Pakistan
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Taiwan
	 	[ * ]

Filed: 11/12/00
	 	Pending
	 
	 	 	 	 	 	 	 	 
	[ * ]

	 	“
	 	Venezuela
	 	[ * ]

Filed: 11/12/00
	 	Pending

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 19 of 24

 

APPENDIX B

Quality Plan

The Quality Plan, as may be amended from time to time by mutual written agreement, is
attached hereto.

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 20 of 24

 

APPENDIX C

Specifications for Finished Products

	 	 	 	 	 	 	 	 	 
	Item

	 	RC-529
	 	Part Number:
	60529	 
	 

	 	TEA Salt Form	 	 	 	 	 	 
	 	 	 	 	Specification Edition
	 

	 	 	 	#:
	03	 

	 	 	 	 	 	 	 
	 	 	 	 	 	 	Manufacturing
	Active Ingredients	 	Amount/Vial	 	Standard Lot Size	 	Instruction
	RC-529 TEA Salt Form

	 	NA
	 	-5 g
	 	MBR 60529
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	Amt/Vial:
	 

	 	 	 	 	 	5 mg, 10 mg or 250

mg

Container/Closure:

	 	 	 	 	 
	Vials:	 	Stoppers:	 	Seals:
	Type 1 BSG: (blow-molded)

	 	Lyophilization
	 	Aluminum 20 mm (52001)
	10 mL (50301) & 100 mL (50304)

	 	Gray butyl 20 mm (51087)	 	 

	 	 	 	 	 	 	 
	Appearance:

	 	Off-white fluffy cake
	 	QC Sample
	 	4 x 5 mg

11 x 10 mg
	 
	 	 	 	 	 	 
	Fill Volume:

	 	10 mg/mL solution filled at 5 mg

10 mg or 250 mg/Vial
	 	Retention

Sample:
	 	10 x 5 mg

22 x 10 mg
	 
	 	 	 	 	 	 
	Final Form:

	 	Lyophilized
	 	Retest Date:
	 	NA
	 
	 	 	 	 	 	 
	Storage

	 	2°-8°C	 	 	 	 
	Conditions:
	 	 	 	 	 	 

Specifications/Testing:

	 	 	 	 	 	 	 
	Product Attribute		Method	 	Specification
	13C NMR 
		SOP #QC-590
	 	Matches Reference Standard
	Purity by HPLC 
		SOP #QC-172
	 	395% by peak area
	Free fatty acids 
		SOP #QC-185
	 	£2.6% (w/w)
	Melting point 
		SOP #QC-151
	 	Information only; report results
	Residual solvent 
		SOP #QC-830
	 	£ 60ppm chloroform
	 

			 	£ 3000 ppm methanol
	 

			 	£ 5000 ppm 1-butanol
	Counter ion 
		SOP #QC-179
	 	2 – 8% (w/w)
	Residual moisture 
		SOP #QC-341
	 	£ 6.7% (w/w)
	ICP Analysis 
		Contract Laboratory
	 	Information only; report results
	Pyrogenicity 
		SOP #QC-660
	 	Nonpyrogenic at 2.5 mg/kg BW
	Bioburden/Sterility 
		SOP #QC-412
	 	£ 10 CFU/10 mg
	 
	Released Product:          Signed for Release
			 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 21 of 24

 

Approval Signatures:

	 	 	 
	 

	 	 
	Purchasing

	 	Date
	 
	 	 
	 

	 	 
	Production

	 	Date
	 
	 	 
	 

	 	 
	Quality Control

	 	Date
	 
	 	 
	 

	 	 
	Quality Assurance

	 	Date
	 
	 	 
	 

	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT OT RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 22 of 24

 

 

Quality Control Analysis Report

Corixa

RC-529 TEA Salt Form – 60529

	 	 	 	 	 	 	 	 	 
	RC-529 Lot No.:

	 	 	 	 
	 	Manufacture Date:	 	 
	 

	 	 
	 	 	 	 	 	 
	QC Sample Quantity:

	 	 	 	 	 	Date Received:	 	 
	 

	 	 
	 	 	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 
	Testing Requirements:	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Tested
	Test	 	Method	 	Edition	 	Specification	 	Results	 	by Date
	 
	1. 13C NMR

	 	SOP #QC-590
	 	 	 	Matches Reference

Standard	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	2. Purity by
HPLC

	 	SOP #QC-172
	 	 	 	3 95% by peak area	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	3. Free fatty acids

	 	SOP #QC-185
	 	 	 	£ 2.6% (w/w)	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	4. Residual solvent

	 	SOP #QC-830
	 	 	 	£ 60 ppm chloroform	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	£ 3000 ppm methanol	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	£ 5000 ppm t-butanol	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	5. Counter ion

	 	SOP #QC-179
	 	 	 	2 – 8 % (w/w)	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	6. Residual moisture

	 	SOP #QC-341
	 	 	 	£ 6.7% (w/w)	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Information only:	 	 	 	 
	7. ICP analysis

	 	Contract Laboratory
	 	 	 	Report results	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	8. Pyrogenicity

	 	SOP #QC-660
	 	 	 	Nonpyrogenic at 2.5
mg/kg BW	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	9. Bioburden/Sterility

	 	SOP #QC-151 and
	 	 	 	£ 10 CFU/10 mg	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Information only:	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 
	10. Melting point

	 	 	 	 	 	Report results	 	 	 	 

Comments

 

 

 

 

 

 

 

Number of sample to retention: 
                
               
               
           
               
        Date:       
               
                
               
       

Test results for RC-529 TEA Salt Form, lot number       
               
                
               
               
            , have been reviewed and (check one)

	 	 	 
	Meet current product specifications o

	 	Do not meet all specifications o

	 	 	 	 	 	 	 	 	 
	QC Manager Review:

	 	 	 	 
	 	Date:	 	 
	 

	 	 
	 	 	 	 	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT OT RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 23 of 24

 

 

Appendix D

Commercial Development Schedule

			
	TERRITORY
	 	ANTICIPATED TIMING

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT OT RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Page 24 of 24exv10w25

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Exhibit 10.25

EXECUTION COPY

 

PURCHASE OPTION AGREEMENT

by and among

DYNAVAX TECHNOLOGIES CORPORATION,

SYMPHONY DYNAMO HOLDINGS LLC

and

SYMPHONY DYNAMO, INC.

 

Dated as of April 18, 2006

 

      

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

 

 

TABLE
OF CONTENTS

	 	 	 	 	 
	 	 	Page
	Section 1. Grant of Purchase Option
	 	 	2	 
	 
	 	 	 	 
	Section 2. Exercise of Purchase Option
	 	 	3	 
	 
	 	 	 	 
	Section 2A. Put Option
	 	 	6	 
	 
	 	 	 	 
	Section 3. Dynavax Representations, Warranties and Covenants
	 	 	7	 
	 
	 	 	 	 
	Section 4. Holdings Representations, Warranties and Covenants
	 	 	9	 
	 
	 	 	 	 
	Section 5. Symphony Dynamo Representations, Warranties and Covenants
	 	 	13	 
	 
	 	 	 	 
	Section 6. Notice of Material Event
	 	 	21	 
	 
	 	 	 	 
	Section 7. Assignment; Transfers; Legend
	 	 	21	 
	 
	 	 	 	 
	Section 8. Costs and Expenses; Payments
	 	 	22	 
	 
	 	 	 	 
	Section 9. Expiration; Termination of Agreement
	 	 	22	 
	 
	 	 	 	 
	Section 10. Survival; Indemnification
	 	 	22	 
	 
	 	 	 	 
	Section 11. No Petition
	 	 	25	 
	 
	 	 	 	 
	Section 12. Third-Party Beneficiary
	 	 	25	 
	 
	 	 	 	 
	Section 13. Notices
	 	 	25	 
	 
	 	 	 	 
	Section 14. Governing Law; Consent to Jurisdiction and Service of Process
	 	 	27	 
	 
	 	 	 	 
	SECTION 15. WAIVER OF JURY TRIAL
	 	 	27	 
	 
	 	 	 	 
	Section 16. Entire Agreement
	 	 	27	 
	 
	 	 	 	 
	Section 17. Amendment; Successors; Counterparts
	 	 	27	 
	 
	 	 	 	 
	Section 18. Specific Performance
	 	 	28	 
	 
	 	 	 	 
	Section 19. Severability
	 	 	28	 
	 
	 	 	 	 
	Section 20. Tax Reporting
	 	 	28	 
	 
	 	 	 	 
	Schedule I Quarterly Price Table
	 	 	 	 
	 
	 	 	 	 
	Annex A Certain Definitions
	 	 	 	 
	 
	 	 	 	 
	Exhibit 1 Purchase Option Exercise Notice
	 	 	 	 
	 
	 	 	 	 
	Exhibit 2 Form of opinion of Cooley Godward LLP
	 	 	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

 

 

PURCHASE OPTION AGREEMENT

          This PURCHASE OPTION AGREEMENT (this “Agreement”) is entered into as of April 18, 2006 (the
“Closing Date”) by and among DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (“Dynavax”),
SYMPHONY DYNAMO HOLDINGS LLC, a Delaware limited liability company (“Holdings”), and SYMPHONY
DYNAMO, INC., a Delaware corporation (“Symphony Dynamo”). Capitalized terms used herein and not
defined herein shall have the meanings assigned to such terms in Annex A attached hereto.

PRELIMINARY STATEMENT

          WHEREAS, Dynavax and Holdings have entered into a Technology License Agreement pursuant to
which Dynavax has granted Holdings an exclusive license (the “License”) to the use of certain
intellectual property related to the Programs owned or controlled by Dynavax;

          WHEREAS, contemporaneously with the execution of this Agreement, Dynavax, Holdings and
Symphony Dynamo are entering into a Novated and Restated Technology License Agreement, pursuant to
which, among other things, Holdings will assign by way of novation the License to Symphony Dynamo;

          WHEREAS, Dynavax and Holdings have entered into a Research and Development Agreement pursuant
to which Dynavax has agreed, among other things, to perform, on behalf of Holdings, research and
development of the Programs;

          WHEREAS, contemporaneously with the execution of this Agreement, Dynavax, Holdings and
Symphony Dynamo are entering into an Amended and Restated Research and Development Agreement,
pursuant to which, among other things, Holdings will assign its rights and obligations under the
Research and Development Agreement to Symphony Dynamo;

          WHEREAS, contemporaneously with the execution of this Agreement, in order to fund such
research and development, institutional investors are committing to invest $50,000,000 in Holdings
(the “Financing”) in exchange for membership interests in Holdings and for a warrant to purchase up
to a total of 2,000,000 shares of Dynavax Common Stock (the “Warrant”), to be initially issued to
Holdings, and Holdings will agree to contribute the net proceeds of the Financing to Symphony
Dynamo;

          WHEREAS, Holdings desires, in consideration for the Warrant, to grant Dynavax an option to
purchase all of the Common Stock of Symphony Dynamo and any other Equity Securities issued by
Symphony Dynamo (together, the “Symphony Dynamo Equity Securities”) owned, or hereinafter acquired,
by Holdings on the terms described in this Agreement; and

          WHEREAS, Symphony Dynamo and Holdings have determined that it is in each of its best interest
to perform and comply with certain agreements and covenants relating to each of its ongoing
operations contained in this Agreement;

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

 

 

          NOW, THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
(the “Parties”) agree as follows:

          Section 1. Grant of Purchase Option.

          (a) Holdings hereby grants to Dynavax an exclusive option (the “Purchase Option”) to purchase
all, but not less than all, of the outstanding Symphony Dynamo Equity Securities owned or
hereinafter acquired by Holdings, in accordance with the terms of this Agreement.

          (b) Symphony Dynamo hereby covenants and agrees that all Symphony Dynamo Equity Securities
issued by Symphony Dynamo at any time prior to the expiration of the Term (including to Holdings
on, prior to, or after the date hereof or to any other Person at any time whatsoever, in all cases
prior to the expiration of the Term) shall be subject to a purchase option on the same terms as the
Purchase Option (except as provided by the immediately following sentence) and all of the other
terms and conditions of this Agreement without any additional action on the part of Dynavax or
Holdings. Further, to the extent Symphony Dynamo shall issue any Symphony Dynamo Equity Securities
(including any issuance in respect of a transfer of Symphony Dynamo Equity Securities by any holder
thereof, including Holdings) after the date hereof to any Person (including Holdings) (any issuance
of such Symphony Dynamo Equity Securities being subject to the prior written consent of Dynavax as
set forth in Sections 5(c) and 7(b) hereof, as applicable), Symphony Dynamo hereby
covenants and agrees that it shall cause such Symphony Dynamo Equity Securities to be subject to
the Purchase Option without the payment of, or any obligation to pay, any additional consideration
in respect of such Symphony Dynamo Equity Securities by Dynavax, Symphony Dynamo or any Symphony
Dynamo Subsidiary to the Person(s) acquiring such subsequently issued Symphony Dynamo Equity
Securities, the Parties acknowledging and agreeing that the sole consideration payable by Dynavax
pursuant to this Agreement for all of the outstanding Symphony Dynamo Equity Securities now or
hereinafter owned by any Person shall be the Purchase Price.

          (c) Dynavax’s right to exercise the Purchase Option granted hereby is subject to the following
conditions:

     (i) The Purchase Option may only be exercised for the purchase of all, and not less
than all, of Holdings’ Symphony Dynamo Equity Securities;

          (ii) The Purchase Option may only be exercised a single time;

     (iii) Except as expressly provided in Section 1(c)(iv), the Purchase Option may be
exercised only during the period (the “Purchase Option Period”) commencing on and including
April 18, 2007, (the “Purchase Option Commencement Date”) and ending on and including the
earlier of (x) April 18, 2011 and (y) the [ * ] day immediately following the first date on
which an internally prepared, unaudited, balance sheet of Symphony
Dynamo (prepared in accordance with GAAP) is delivered to Dynavax stating that the
aggregate amount of (A) cash and cash equivalents held by Symphony Dynamo and (B)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

2

 

cash that
will be received in connection with a pending Funding Notice provided by Holdings to the
Investors pursuant to the Funding Agreement is less than [ * ]; and

     (iv) In the event that Holdings terminates the Amended and Restated Research and
Development Agreement pursuant to Section 17.2 thereof, Dynavax [ * ] to notify Holdings of
its exercise of the Purchase Option under the terms of this Agreement. Such exercise of the
Purchase Option by Dynavax may occur prior to the Purchase Option Commencement Date (an
“Early Purchase Option Exercise”).

          Section 2. Exercise of Purchase Option.

          (a) Exercise Notice. Dynavax may exercise the Purchase Option only by delivery of a
notice in the form attached hereto as Exhibit 1 (the “Purchase Option Exercise Notice”)
during the Purchase Option Period. The Purchase Option Exercise Notice shall be delivered on a
Business Day to Holdings and Symphony Dynamo and shall be irrevocable once delivered. The date on
which the Purchase Option Exercise Notice is first delivered to Holdings and Symphony Dynamo is
referred to as the “Purchase Option Exercise Date.” The Purchase Option Exercise Notice shall
contain (1) an estimated date for the settlement of the Purchase Option (the “Purchase Option
Closing”), which date shall be estimated in accordance with this Section 2(a), (2) the
Purchase Price, determined in accordance with Section 2(b) hereof, and (3) if Dynavax
intends to pay part of the Purchase Price in Dynavax Common Stock, notice of such intent, the
number of shares to be transferred as such purchase price, the valuation thereof and the percentage
such portion bears to (A) the Purchase Price, and (B) the total amount of Dynavax Common Stock then
issued and outstanding (which shall be no greater percentages than are permitted under Section
2(c)). Such notice and election shall be irrevocable once given and made. If, during the
period following delivery of the Purchase Option Exercise Notice, the amount of cash and cash
equivalents held by Symphony Dynamo is an amount less than or equal to [ * ] then Symphony Dynamo
shall cease payment of any amounts owed to Dynavax in respect of its activities pursuant to the
Amended and Restated Research and Development Agreement, but shall continue to pay amounts owed to
all other Persons. The date of the Purchase Option Closing (the “Purchase Option Closing Date”)
shall be determined as follows:

     (i) If Dynavax elects to pay the entire Purchase Price in cash, the Purchase Option
Closing Date shall be the date [ * ]; and (B) if Dynavax determines that an HSR Filing is
required, [ * ] following the date that Dynavax receives the necessary Government Approvals
related to its HSR Filings; provided, however that Dynavax and Holdings
shall make all necessary HSR Filings within [ * ] following the Purchase Option Exercise
Date and shall diligently pursue the related regulatory process; and provided,
further that (1) if there is no second request from the Federal Trade Commission or
the Department of Justice, as applicable, with respect to Dynavax’s or Holdings’ HSR
Filings, then in no event shall the Purchase Option Closing Date be more than [ * ]
following the Purchase Option Exercise Date, and (2) if there is a second request from the
Federal Trade Commission or the Department of Justice, as applicable,
with respect to Dynavax’s or Holdings’ HSR Filings, then in no event shall the Purchase
Option Closing Date be more than [ * ] days following the Purchase Option Exercise Date. If
Dynavax shall fail to make such cash payment within such [ * ] day period or [ * ] day
period, as applicable, then in addition to any other rights that Holdings shall have

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

3

 

hereunder, this Agreement shall terminate and Dynavax shall relinquish all rights hereunder
to purchase the Symphony Dynamo Equity Securities; or

     (ii) If Dynavax elects to pay a portion of the Purchase Price in Dynavax Common Stock
(subject to the limitations set forth herein and in the Registration Rights Agreement), the
Purchase Option Closing Date shall be the date that is the later of:

     (A) [ * ] following the Effective Registration Date of such Dynavax Common
Stock; provided, that Dynavax shall file the Registration Statement
contemplated by Section 3(b)(i) within (x) [ * ] Business Days after the
Purchase Option Exercise Date if Dynavax is eligible to use Form S-3 under the
Securities Act (or any successor form), or (y) [ * ] Business Days after the
Purchase Option Exercise Date if Dynavax is not eligible to use Form S-3 under the
Securities Act (or any successor form); and

     (B) [ * ] following the date that Dynavax receives the necessary Government
Approvals related to its HSR Filings; provided, however, that
Dynavax and Holdings shall make all necessary HSR Filings within [ * ] following the
Purchase Option Exercise Date and shall diligently pursue the related regulatory
process;

provided, further, that Dynavax shall use commercially reasonable efforts to
have such Registration Statement declared effective by the United States Securities and
Exchange Commission as promptly as possible. In the event that such Registration Statement
is not declared effective within [ * ] days of the Purchase Option Exercise Date, Dynavax
shall pay the full Purchase Price in cash within two (2) Business Days thereafter (in which
event the Purchase Option Closing Date shall be the date upon which such cash payment is
made by Dynavax). If Dynavax shall fail to make such cash payment within such two (2)
Business Day period, then in addition to any other rights that Holdings shall have
hereunder, this Agreement shall terminate and Dynavax shall relinquish all rights hereunder
to purchase the Symphony Dynamo Equity Securities.

          (b) Purchase Price Upon Option Exercise. Upon exercise of the Purchase Option and as
complete and full consideration for the sale to Dynavax by Holdings of its Symphony Dynamo Equity
Securities (and for the Symphony Dynamo Equity Securities of any other Person), Dynavax shall pay
to Holdings the “Purchase Price”, as follows:

     (i) If the Purchase Option is exercised on or after the Purchase Option Commencement
Date and prior to the date that is the first date [ * ] (the “Purchase Option Interim
Date”), then the Purchase Price shall be an amount equal to (x) the amount set forth on
Schedule I applicable to [ * ] (the “Quarterly Price”), plus (y) an amount equal to
the amount of the [ * ] by [ * ]; provided, that in no event shall the total
Purchase Price under this Section 2(b)(i) exceed [ * ], as set forth on Schedule
I hereto; or

     (ii) If the Purchase Option is exercised on or after the Purchase Option Interim Date,
then the Purchase Price shall be an amount equal to the applicable Quarterly Price;
or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

4

 

     (iii) In the event of an Early Purchase Option Exercise, pursuant to Section
1(c)(iv) hereof, the Purchase Price shall be an amount equal to the amount set forth on
Schedule I [ * ].

          (c) Form of Payment. Subject to Sections 2(a) and 2(e), the Purchase
Price may be paid in cash or in a combination of cash and Dynavax Common Stock, at the sole
discretion of Dynavax; provided, that in no event may the value of Dynavax Common Stock
(determined in accordance with Section 2(e) hereof) delivered in connection with the
exercise of the Purchase Option constitute more than either [ * ].

          (d) Surrender of Symphony Dynamo Equity Securities. Subject to the terms and
conditions of this Agreement, on or prior to the Purchase Option Closing Date, Holdings shall
surrender to Dynavax its certificates representing its Symphony Dynamo Equity Securities, and shall
convey good title to such Symphony Dynamo Equity Securities, free from any Encumbrances and from
any and all restrictions that any sale, assignment or other transfer of such Symphony Dynamo Equity
Securities be consented to or approved by any Person. On or prior to the Purchase Option Closing
Date, Holdings shall remove all directors serving on the Symphony Dynamo Board, other than the
Dynavax Director (as defined in Section 4(b)(iv) hereof) from the Symphony Dynamo Board as
of the Purchase Option Closing Date.

          (e) Valuation of Dynavax Stock. In the event that Dynavax elects to pay part of the
Purchase Price through the delivery to Holdings of Dynavax Common Stock, the value per share
thereof (the “Dynavax Common Stock Valuation”) shall equal the average closing price of Dynavax
Common Stock, as reported by the NASDAQ National Market, or other national exchange that is the
primary exchange on which Dynavax Common Stock is listed, for the thirty (30) trading days
immediately preceding the second trading day prior to the Purchase Option Exercise Date. If
Dynavax Common Stock is not traded on a national exchange or the NASDAQ National Market, then
Dynavax shall be obligated to pay the Purchase Price solely in cash on the Purchase Option Closing
Date. Dynavax shall calculate the Dynavax Common Stock Valuation in accordance with this
Section 2(e), subject to review and confirmation by Holdings.

          (f) Share Certificates. Any stock certificate(s) issued by Dynavax for Dynavax Common
Stock pursuant to this Section 2 may contain a legend (the “33 Act Legend”) substantially
as follows:

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE, AND
THE SAME HAVE BEEN ISSUED IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION
REQUIREMENTS OF SAID ACT AND SUCH LAWS.
SUCH SHARES MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE
DISPOSED OF EXCEPT AS PERMITTED UNDER SUCH SECURITIES LAWS, PURSUANT TO REGISTRATION
OR EXEMPTION THEREFROM.

This legend shall be removed by Dynavax, subject to, and in accordance with, the terms of
Section 3(b)(iii) hereof.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

5

 

          (g) Government Approvals. On or prior to the Purchase Option Closing Date, each of
Dynavax, Symphony Dynamo and Holdings shall have taken all necessary action to cause all
Governmental Approvals with respect to such Party (including, if deemed necessary and without
limitation, the preparing and filing of the pre-merger notification and report forms required under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Filings”)) required to
be in effect in connection with the transactions contemplated by this Agreement to be in effect;
provided, however, that with respect to Government Approvals required by a
Governmental Authority other than the United States federal government and its various branches and
agencies, the Parties’ obligations under this Section 2(g) shall be limited to causing to
be in effect only those Government Approvals, the failure of which to be in effect would, either
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on any
of the Parties. Each of Symphony Dynamo and Dynavax shall pay its own costs associated with
taking such action. Symphony Dynamo shall pay any costs of Holdings associated with obtaining
Government Approvals required in connection with the exercise of the Purchase Option. All other
costs and expenses of Holdings shall be paid by Holdings pursuant to Section 8(b) hereof,
including any costs arising from any error in Holdings’ initial valuation of its investment in
Symphony Dynamo.

          (h) Transfer of Title. Transfer of title to Dynavax of all of the Symphony Dynamo
Equity Securities shall be deemed to occur automatically on the Purchase Option Closing Date,
subject to the payment by Dynavax on such date of the Purchase Price and its performance of its
other obligations herein required to be performed under Sections 2(e) and (g), and
under the Registration Rights Agreement, as applicable, on or prior to the Purchase Option Closing
Date to the reasonable satisfaction of Holdings, and thereafter Symphony Dynamo shall treat Dynavax
as the sole holder of all Symphony Dynamo Equity Securities, notwithstanding the failure of
Holdings to tender certificates representing such shares to Dynavax in accordance with Section
2(d) hereof. After the Purchase Option Closing Date, Holdings shall have no rights in
connection with such Symphony Dynamo Equity Securities other than the right to receive the Purchase
Price; provided, however, that nothing in this Section 2(h) shall affect
the survivability of any indemnification provision in this Agreement upon termination of this
Agreement.

          (i) Consents and Authorizations. On or prior to the Purchase Option Closing Date,
Dynavax shall have obtained all consents and authorizations necessary from stockholders and/or its
board of directors for the consummation of the exercise and closing of the Purchase Option, as may
be required under the organizational documents of Dynavax, any prior stockholders or board
resolution, any stock exchange or similar rules or any applicable law; provided,
however, that with respect to consents or authorizations required by a Governmental
Authority other than the United States federal government and its various branches and agencies,
the Parties’ obligations under this Section 2(i) shall be limited to obtaining only those
consents
and authorizations, the failure of which to be obtained would, either individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on any of the Parties.

          Section 2A. Put Option.

          (a) Holdings has an exclusive put option (the “Put Option”) for 100% of the Symphony Dynamo
Equity Securities which may be exercised if, [ * ] after Holdings has delivered written notice
thereof to such successor entity.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

6

 

          (b) Holdings may exercise the Put Option only by delivery of written notice (the “Put Option
Exercise Notice”) during the Purchase Option Period. The Put Option Exercise Notice shall be
delivered on a Business Day to the successor entity to Dynavax, with a copy to Symphony Dynamo, and
shall thereafter be deemed for all purposes under the terms of this Agreement to be a Purchase
Option Exercise Notice by Dynavax (in accordance with the provisions of Section 2 hereof)
as of the date such notice is delivered (such date to be deemed for all purposes under the terms of
this Agreement as the Purchase Option Exercise Date), and all references to Dynavax and Dynavax
Common Stock in Section 2 shall be deemed references to the successor entity to Dynavax and
its common stock, respectively. The Purchase Price with respect to such an exercise of the Put
Option shall be the Purchase Price otherwise applicable (under Section 2(b) hereof) to the
Purchase Option Closing Date selected by Dynavax following Dynavax’s receipt of the Put Option
Exercise Notice.

          Section 3. Dynavax Representations, Warranties and Covenants.

          (a) As of the date hereof, Dynavax hereby represents and warrants, and, except to the extent
that any of the following representations and warranties is limited to the date of this Agreement
or otherwise limited, on the Purchase Option Closing Date, shall be deemed to have represented and
warranted, to Holdings and Symphony Dynamo that:

     (i) Organization. Dynavax is a corporation, duly organized, validly existing
and in good standing under the laws of the State of Delaware.

     (ii) Authority and Validity. Dynavax has all requisite corporate power and
authority to execute, deliver and perform its obligations under this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and performance by
Dynavax of this Agreement and the consummation of the transactions contemplated hereby have
been duly and validly authorized by all necessary action required on the part of Dynavax,
and no other proceedings on the part of Dynavax are necessary to authorize this Agreement or
for Dynavax to perform its obligations under this Agreement. This Agreement constitutes the
lawful, valid and legally binding obligation of Dynavax, enforceable in accordance with its
terms, except as the same may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights
generally and general equitable
principles regardless of whether such enforceability is considered in a proceeding at
law or in equity.

     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate, conflict with or
result in the breach of any provision of the Organizational Documents of Dynavax, (B) as of
the date of this Agreement, and as of the Purchase Option Closing Date if Dynavax elects to
pay part of the Purchase Price through the delivery of Dynavax Common Stock (a “Partial
Stock Payment”), conflict with or violate any law or Governmental Order applicable to
Dynavax or any of its assets, properties or businesses, or (C) conflict with, result in any
breach of, constitute a default (or event that with the giving of notice or lapse of time,
or both, would become a default) under, require any consent under, or give to others any
rights of termination, amendment, acceleration, suspension, revocation or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

7

 

cancellation of,
or result in the creation of any Encumbrance on any of the assets or properties of Dynavax,
pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease,
license, permit, franchise or other instrument or arrangement to which Dynavax is a party
except, in the case of clauses (B) and (C), to the extent that such
conflicts, breaches, defaults or other matters would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Dynavax.

     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Dynavax do not, and the consummation of the transactions
contemplated hereby (which transactions shall not include the exercise of the Purchase
Option) do not and will not, require any Governmental Approval which has not already been
obtained, effected or provided, except with respect to which the failure to so obtain,
effect or provide would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect on Dynavax.

     (v) Litigation. As of the date of this Agreement, and as of the Purchase
Option Closing Date if Dynavax elects to make a Partial Stock Payment, there are no actions
by or against Dynavax pending before any Governmental Authority or, to the knowledge of
Dynavax, threatened to be brought by or before any Governmental Authority, that would,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect
on Dynavax. There are no pending or, to the knowledge of Dynavax, threatened actions, to
which Dynavax is a party (or is threatened to be named as a party) to set aside, restrain,
enjoin or prevent the execution, delivery or performance of this Agreement or the Operative
Documents or the consummation of the transactions contemplated hereby or thereby by any
party hereto or thereto. As of the date of this Agreement, and as of the Purchase Option
Closing Date if Dynavax elects to make a Partial Stock Payment, Dynavax is not subject to
any Governmental Order (nor, to the knowledge of Dynavax, is there any such Governmental
Order threatened to be imposed by any Governmental Authority) that would, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect on Dynavax.

          (b) Dynavax hereby covenants and agrees with Holdings as follows:

     (i) Immediately prior to the Purchase Option Closing Date, Dynavax shall have
sufficient amounts of cash and, if applicable, authorized but unissued, freely transferable
and nonassessable Dynavax Common Stock available to satisfy the portion of the Purchase
Price to be paid in cash or Dynavax Common Stock pursuant to Sections 2(b) and
2(c). In the event that Dynavax elects to satisfy any portion of the Purchase Price
in Dynavax Common Stock, (A) Dynavax shall have not later than the Purchase Option Closing
Date, a Registration Statement declared effective by the Securities and Exchange Commission
for the resale of any such shares of Dynavax Common Stock to be delivered in partial
satisfaction of the Purchase Price, accompanied by evidence reasonably acceptable to
Holdings that such Dynavax Common Stock has been approved for listing on the NASDAQ national
market or such other national market on which the Dynavax Common Stock is then listed, and
(B) Dynavax shall deliver to Holdings on or prior to the Purchase Option Closing Date, a
legal opinion of Cooley Godward LLP (or such other counsel as Dynavax and Holdings shall
mutually agree) on the issuance and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

8

 

sale of such Dynavax Common Stock, which opinion shall
be, in form and substance reasonably acceptable to Holdings.

     (ii) If Dynavax elects to satisfy any portion of the Purchase Price in Dynavax Common
Stock, Dynavax shall convey good and marketable title to such Dynavax Common Stock, free
from any Encumbrances and any and all other restrictions that any issuance, sale, assignment
or other transfer of such Dynavax Common Stock be consented to or approved by any Person.

     (iii) If the share certificates representing such Dynavax Common Stock include the 33
Act Legend (as set forth in Section 2(f) hereof), Dynavax shall, within two (2)
Business Days of receiving a request from Holdings or any “Investor” (as defined in the
Registration Rights Agreement), remove or cause to be removed the 33 Act Legend from the
such share certificates as Holdings or such Investor shall designate, so long as (x) the
Dynavax Common Stock represented by such share certificates has been transferred to a third
party in compliance with the registration requirements of the Securities Act or an available
exemption therefrom, and (y) Dynavax receives a certification from Holdings, such Investor
or a securities broker designated by Holdings or such Investor to the effect that the sale
of such Dynavax Common Stock was made under a Registration Statement and accompanied by the
delivery of a current prospectus.

     (iv) Upon the expiration of the Purchase Option or the termination of this Agreement
pursuant to Section 9 hereof, or as soon thereafter as is practical, Dynavax shall
(A) in accordance with Sections 2.7 and 2.8 of the Novated and Restated Technology License
Agreement, deliver to Symphony Dynamo all regulatory submissions, clinical master files,
development plans, consultant inputs, manufacturing reports and, to the extent requested by
Symphony, other materials, documents, files and other information relating to the Programs
and necessary to enable Symphony Dynamo to continue the development of the Programs (or,
where necessary, copies thereof), and (B) in accordance with and pursuant to Section 2.12 of
the Novated and Restated Technology License Agreement, negotiate in good faith, and on
commercially reasonable terms and conditions, a supply agreement relating to materials,
including compounds and Products, required by Symphony Dynamo or its partners or transferees
for the continued
development (including clinical development), manufacture and commercialization of
Products.

     (v) In the event that Dynavax exercises the Purchase Option, then Dynavax shall
maintain the separate corporate existence of Symphony Dynamo for a minimum of two (2) years
following such exercise, unless such maintenance would have a Material Adverse Effect on
Dynavax or any of its Affiliates.

          Section 4. Holdings Representations, Warranties and Covenants.

          (a) As of the date hereof, Holdings hereby represents and warrants, and, except to the extent
that any of the following representations and warranties is limited to the date of this Agreement
or otherwise limited, on the Purchase Option Closing Date, shall be deemed to have represented and
warranted, to Dynavax and Symphony Dynamo that:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

9

 

     (i) Organization. Holdings is a limited liability company, duly formed,
validly existing and in good standing under the laws of the State of Delaware.

     (ii) Authority and Validity. Holdings has all requisite limited liability
company power and authority to execute, deliver and perform its obligations under this
Agreement and to consummate the transactions contemplated hereby. The execution, delivery
and performance by Holdings of this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly authorized by all necessary action required
on the part of Holdings, and no other proceedings on the part of Holdings are necessary to
authorize this Agreement or for Holdings to perform its obligations under this Agreement.
This Agreement constitutes the lawful, valid and legally binding obligation of Holdings,
enforceable in accordance with its terms, except as the same may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement
of creditors’ rights generally and general equitable principles regardless of whether such
enforceability is considered in a proceeding at law or in equity.

     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate, conflict with or
result in the breach of any provision of the Organizational Documents of Holdings, (B) as of
the date of this Agreement, conflict with or violate any law or Governmental Order
applicable to Holdings or any of its assets, properties or businesses, or (C) as of the date
of this Agreement, conflict with, result in any breach of, constitute a default (or event
that with the giving of notice or lapse of time, or both, would become a default) under,
require any consent under, or give to others any rights of termination, amendment,
acceleration, suspension, revocation or cancellation of, or result in the creation of any
Encumbrance on any of the assets or properties of Holdings, pursuant to, any note, bond,
mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or
other instrument or arrangement to which Holdings is a party except, in the case of
clauses (B) and (C), to the extent that such conflicts, breaches, defaults
or other matters would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect on Holdings.

     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Holdings do not, and the consummation of the transactions
contemplated hereby do not and will not, require any Governmental Approval which has not
already been obtained, effected or provided, except with respect to which the failure to so
obtain, effect or provide would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Holdings.

     (v) Litigation. As of the date of this Agreement, there are no actions by or
against Holdings pending before any Governmental Authority or, to the knowledge of Holdings,
threatened to be brought by or before any Governmental Authority, that would, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect on Holdings.
There are no pending or, to the knowledge of Holdings, threatened actions to which Holdings
is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or
prevent the execution, delivery or performance of this Agreement or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

10

 

the Operative Documents
or the consummation of the transactions contemplated hereby or thereby by any party hereto
or thereto. As of the date of this Agreement, Holdings is not subject to any Governmental
Order (nor, to the knowledge of Holdings, is there any such Governmental Order threatened to
be imposed by any Governmental Authority) that would, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Holdings.

     (vi) Stock Ownership. All of Symphony Dynamo’s issued and outstanding
Symphony Dynamo Equity Securities are owned beneficially and of record by Holdings, free and
clear of any and all encumbrances.

     (vii) Interim Operations. Holdings was formed solely for the purpose of
engaging in the transactions contemplated by the Operative Documents, has engaged in no
other business activities and has conducted its operations only as contemplated by the
Operative Documents.

     (viii) Accredited Investor.

     (A) Holdings is and will remain at all relevant times an Accredited Investor.

     (B) Holdings has relied completely on the advice of, or has consulted with or
has had the opportunity to consult with, its own personal tax, investment, legal or
other advisors and has not relied on Dynavax or any of its Affiliates for advice
related to any offer and sale of Dynavax Common Stock in connection with the
Purchase Option. Holdings has reviewed the Investment Overview and is aware of the
risks disclosed therein. Holdings acknowledges that it has had a reasonable
opportunity to conduct its own due diligence with respect to the Products, the
Programs, Symphony Dynamo, Dynavax and the transactions contemplated by the
Operative Documents.

     (C) Holdings is able to bear the economic risk of such investment for an
indefinite period and to afford a complete loss thereof

     (D) Holdings agrees that the Dynavax Common Stock may not be resold (1) without
registration thereof under the Securities Act (unless an exemption from such
registration is available), or (2) in violation of any law.

     (E) No person or entity acting on behalf of, or under the authority of,
Holdings is or will be entitled to any broker’s, finder’s, or similar fees or
commission payable by Dynavax or any of its Affiliates.

          (b) Holdings hereby covenants and agrees with Dynavax as follows:

     (i) Contribution to Symphony Dynamo. On or prior to the Stock Payment Date,
Holdings shall, pursuant to the Subscription Agreement, use the Initial Funds (as defined in
the Funding Agreement) to pay to Symphony Dynamo the Stock Purchase Price (in accordance
with, and as defined in, the Subscription Agreement), in respect of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

11

 

the 50,000 shares of
Common Stock delivered to Holdings by Symphony Dynamo as of the Closing Date. Additionally,
(1) upon the earlier of (x) the date on which Holdings receives a request for additional
funds from Symphony Dynamo, and (y) February 26, 2007, Holdings shall, promptly (but in no
event later than the fifth (5th) day after the receipt of such request) and in
accordance with the terms of Section 2 of the Funding Agreement, submit to Investors a
Funding Notice; provided, that if Holdings has received a Purchase Option Exercise
Notice, it shall not submit to Investors a Funding Notice, and (2) upon Holdings receiving
any additional net proceeds from any financing received from Investors in accordance with
the Funding Agreement for the purpose of the contribution of such proceeds to Symphony
Dynamo, Holdings shall contribute promptly such proceeds thereof to Symphony Dynamo.

     (ii) Encumbrance. Holdings will not, and will not permit any of its
Subsidiaries to, create, assume or suffer to exist any Encumbrance on any of its Symphony
Dynamo Equity Securities except with the prior written consent of Dynavax.

     (iii) Transfer and Amendment. Commencing upon the date hereof and ending upon
the earlier to occur of (x) the Purchase Option Closing Date, (y) the unexercised expiration
of the Purchase Option Period, and (z) the termination of this Agreement pursuant to
Section 9(b) (such period, the “Term”), the manager of Holdings shall not (A)
transfer, or permit the transfer of, any Membership Interest without the prior written
consent of Dynavax or (B) amend, or permit the amendment of, any provisions relating to the
transfer of Membership Interests, as set forth in Section 7.02 of the Holdings LLC
Agreement, to the extent such amendment would adversely affect Dynavax’s right of consent
set forth in Sections 7.02(b)(i) and 7.02(c) of the Holdings LLC Agreement.

     (iv) Symphony Dynamo Directors. During the Term, Holdings agrees to vote all
of its Symphony Dynamo Equity Securities (or to exercise its right with respect to such
Symphony Dynamo Equity Securities to consent to action in writing without a meeting) in
favor of, as applicable, the election, removal and replacement of one director
of the Symphony Dynamo Board, and any successor thereto, designated by Dynavax (the
“Dynavax Director”) as directed by Dynavax. In furtherance and not in limitation of the
foregoing, Holdings hereby grants to Dynavax an irrevocable proxy, with respect to all
Symphony Dynamo Equity Securities now owned or hereafter acquired by Holdings, to vote such
Symphony Dynamo Equity Securities or to exercise the right to consent to action in writing
without a meeting with respect to such Symphony Dynamo Equity Securities, such irrevocable
proxy to be exercised solely for the limited purpose of electing, removing and replacing the
Dynavax Director in the event of the failure or refusal of Holdings to elect, remove or
replace such Dynavax Director, as directed by Dynavax. Additionally, Holdings agrees,
during the Term, to the selection of two (2) independent directors (of the four (4)
directors of Symphony Dynamo not chosen by Holdings at the direction of Dynavax), and any
successors thereto. Such independent directors shall be selected by mutual agreement of
Dynavax and Holdings.

     (v) Symphony Dynamo Board. During the Term, Holdings shall not vote any of its
Symphony Dynamo Equity Securities (or exercise its rights with respect to such Symphony
Dynamo Equity Securities by written consent without a meeting) to increase

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

12

 

the size of the
Symphony Dynamo Board to more than five (5) members without the prior written consent of
Dynavax.

     (vi) Symphony Dynamo Charter. During the Term, Holdings shall not approve or
permit any amendment to Article IV, Paragraphs (1) and (3); Article VI; Article VII; Article
X; Article XI or Article XIII of the Symphony Dynamo Charter without the prior written
consent of Dynavax.

          Section 5. Symphony Dynamo Representations, Warranties and Covenants.

          (a) As of the date hereof, Symphony Dynamo hereby represents and warrants, and, except to the
extent that any of the following representations and warranties is limited to the date of this
Agreement or otherwise limited, on the Purchase Option Closing Date, shall be deemed to have
represented and warranted, to Dynavax and Holdings that:

     (i) Organization. Symphony Dynamo is a corporation, duly organized, validly
existing and in good standing under the laws of the State of Delaware.

     (ii) Authority and Validity. Symphony Dynamo has all requisite corporate power
and authority to execute, deliver and perform its obligations under this Agreement and to
consummate the transactions contemplated hereby. The execution, delivery and performance by
Symphony Dynamo of this Agreement and the consummation of the transactions contemplated
hereby have been duly and validly authorized by all necessary action required on the part of
Symphony Dynamo, and no other proceedings on the part of Symphony Dynamo are necessary to
authorize this Agreement or for Symphony Dynamo to perform its obligations under this
Agreement. This Agreement constitutes the lawful, valid and legally binding obligation of
Symphony Dynamo, enforceable in accordance with its terms, except as the same may be limited
by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting the enforcement of
creditors’ rights generally and general equitable principles regardless of whether such
enforceability is considered in a proceeding at law or in equity.

     (iii) No Violation or Conflict. The execution, delivery and performance of
this Agreement and the transactions contemplated hereby do not (A) violate, conflict with or
result in the breach of any provision of the Organizational Documents of Symphony Dynamo,
(B) conflict with or violate any law or Governmental Order applicable to Symphony Dynamo or
any of its assets, properties or businesses, or (C) conflict with, result in any breach of,
constitute a default (or event that with the giving of notice or lapse of time, or both,
would become a default) under, require any consent under, or give to others any rights of
termination, amendment, acceleration, suspension, revocation or cancellation of, or result
in the creation of any Encumbrance on any of the assets or properties of Symphony Dynamo,
pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease,
license, permit, franchise or other instrument or arrangement to which Symphony Dynamo is a
party except, in the case of clauses (B) and (C), to the extent that such
conflicts, breaches, defaults or other matters would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

13

 

     (iv) Governmental Consents and Approvals. The execution, delivery and
performance of this Agreement by Symphony Dynamo do not, and the consummation of the
transactions contemplated hereby do not and will not, require any Governmental Approval
which has not already been obtained, effected or provided, except with respect to which the
failure to so obtain, effect or provide would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.

     (v) Litigation. There are no actions by or against Symphony Dynamo pending
before any Governmental Authority or, to the knowledge of Symphony Dynamo, threatened to be
brought by or before any Governmental Authority that would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.
There are no pending or, to the knowledge of Symphony Dynamo, threatened actions to which
Symphony Dynamo is a party (or is threatened to be named as a party) to set aside, restrain,
enjoin or prevent the execution, delivery or performance of this Agreement or the Operative
Documents or the consummation of the transactions contemplated hereby or thereby by any
party hereto or thereto. Symphony Dynamo is not subject to any Governmental Order (nor, to
the knowledge of Symphony Dynamo, is there any such Governmental Order threatened to be
imposed by any Governmental Authority) that would, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.

     (vi) Capitalization. Holdings is the beneficial and record owner of all issued
and outstanding Symphony Dynamo Equity Securities. No shares of Symphony Dynamo capital
stock are held in treasury by Symphony Dynamo or any Symphony Dynamo Subsidiary. All of
the issued and outstanding Symphony Dynamo Equity Securities (A) have been duly authorized
and validly issued and are fully paid and nonassessable, (B)
were issued in compliance with all applicable state and federal securities laws, and
(C) were not issued in violation of any preemptive rights or rights of first refusal. No
preemptive rights or rights of first refusal exist with respect to any Symphony Dynamo
Equity Securities and no such rights will arise by virtue of or in connection with the
transactions contemplated hereby (other than for the Purchase Option). Other than the
Purchase Option, there are no outstanding options, warrants, call rights, commitments or
agreements of any character to acquire any Symphony Dynamo Equity Securities. There are no
outstanding stock appreciation, phantom stock, profit participation or other similar rights
with respect to Symphony Dynamo. Symphony Dynamo is not obligated to redeem or otherwise
acquire any of its outstanding Symphony Dynamo Equity Securities.

     (vii) Interim Operations. Symphony Dynamo was formed solely for the purpose of
engaging in the transactions contemplated by the Operative Documents, has engaged in no
other business activities and has conducted its operations only as contemplated by the
Operative Documents.

     (viii) Investment Company. Symphony Dynamo is not, and after giving effect to
the transactions contemplated by the Operative Documents will not be, required to register
as an “investment company” as such term is defined in the Investment Company Act of 1940, as
amended.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

14

 

          (b) Symphony Dynamo covenants and agrees that:

     (i) Symphony Dynamo will comply with all laws, ordinances or governmental rules or
regulations to which it is subject and will obtain and maintain in effect all licenses,
certificates, permits, franchises and other Governmental Approvals necessary to the
ownership of its properties or to the conduct of its business, in each case to the extent
necessary to ensure that non-compliance with such laws, ordinances or governmental rules or
regulations or failures to obtain or maintain in effect such licenses, certificates,
permits, franchises and other Governmental Approvals would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Dynamo.

     (ii) Symphony Dynamo will file (or cause to be filed) all material tax returns required
to be filed by it and pay all taxes shown to be due and payable on such returns and all
other taxes imposed on it or its assets to the extent such taxes have become due and payable
and before they have become delinquent and shall pay all claims for which sums have become
due and payable that have or might become attached to the assets of Symphony Dynamo;
provided, that Symphony Dynamo need not file any such tax returns or pay any such
tax or claims if (A) the amount, applicability or validity thereof is contested by Symphony
Dynamo on a timely basis in good faith and in appropriate proceedings, and Symphony Dynamo
has established adequate reserves therefor in accordance with GAAP on the books of Symphony
Dynamo or (B) the failure to file such tax returns or the nonpayment of such taxes and
assessments, individually or in the aggregate, could not reasonably be expected to have a
Material Adverse Effect on Symphony Dynamo.

     (iii) Symphony Dynamo will at all times preserve and keep in full force and effect its
corporate existence.

     (iv) Symphony Dynamo will keep complete, proper and separate books of record and
account, including a record of all costs and expenses incurred, all charges made, all
credits made and received, and all income derived in connection with the operation of the
business of Symphony Dynamo, all in accordance with GAAP, in each case to the extent
necessary to enable Symphony Dynamo to comply with the periodic reporting requirements of
this Agreement.

     (v) Symphony Dynamo will perform and observe in all material respects all of the terms
and provisions of each Operative Document to be performed or observed by it, maintain each
such Operative Document to which it is a party, promptly enforce in all material respects
each such Operative Document in accordance with its terms, take all such action to such end
as may be from time to time reasonably requested by Holdings or Dynavax and make to each
other party to each such Operative Document such demands and requests for information and
reports or for action as Symphony Dynamo is entitled to make under such Operative Document.

     (vi) Symphony Dynamo shall permit the representatives of Holdings (including Holdings’
members and their respective representatives), each Symphony

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

15

 

Fund and Dynavax, at each of
their own expense and upon reasonable prior notice to Symphony Dynamo, to visit the
principal executive office of Symphony Dynamo, to discuss the affairs, finances and accounts
of Symphony Dynamo with Symphony Dynamo’s officers and (with the consent of Symphony Dynamo,
which consent will not be unreasonably withheld) the Symphony Dynamo Auditors (as defined in
Section 5(d)(iii) hereof), all at such reasonable times and as often as may be
reasonably requested in writing.

     (vii) Symphony Dynamo shall permit each Symphony Fund, at its own expense and upon
reasonable prior notice to Symphony Dynamo, to inspect and copy Symphony Dynamo’s books and
records and inspect Symphony Dynamo’s properties at reasonable times.

     (viii) Symphony Dynamo shall allow Dynavax or its designated representatives to have
reasonable visitation and inspection rights with regard to the Programs and materials,
documents and other information relating thereto.

     (ix) Symphony Dynamo shall permit each Symphony Fund to consult with and advise the
management of Symphony Dynamo on matters relating to the research and development of the
Programs in order to develop the Product.

     (x) On the Purchase Option Closing Date, or as soon thereafter as is practical,
Symphony Dynamo shall deliver to Dynavax all materials, documents, files and other
information relating to the Programs (or, where necessary, copies thereof).

     (xi) During the Term, Dynavax shall have the right to consent to any increase in the
size of the Symphony Dynamo Board to more than five (5) directors.

     (xii) During the Term, Dynavax shall have the right to designate, remove and replace
one (1) director of the Symphony Dynamo Board and consent to the selection of the two (2)
independent directors (of the four (4) directors of Symphony Dynamo not chosen by Holdings
at the direction of Dynavax), in each case including any successors thereto and in
accordance with the terms of Section 4(b)(iv).

     (xiii) Symphony Dynamo shall indemnify the directors and officers of Symphony Dynamo
against liability incurred by reason of the fact that such Person is or was a director or
officer of Symphony Dynamo, as permitted by Article VII of the Symphony Dynamo Charter and
Section 9.01 of the Symphony Dynamo By-laws, as set forth in, and on the terms of, the
Indemnification Agreement and the RRD Services Agreement, respectively.

     (xiv) During the Term, Symphony Dynamo shall comply with, and cause any Persons acting
for it to comply with, the terms of the Investment Policy with respect to the investment of
any funds held by it.

          (c) Symphony Dynamo covenants and agrees that, until the expiration of the Term, it shall not,
and shall cause its Subsidiaries (if any) not to, without Dynavax’s prior written consent (such
consent, in the case of clause (x) below, not to be unreasonably withheld):

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

16

 

     (i) issue any Symphony Dynamo Equity Securities or any Equity Securities of any
Subsidiary thereof (other than any issuances of Equity Securities by Symphony Dynamo made in
accordance with Section 1(b) hereof to Holdings so long as Symphony Dynamo is a
wholly owned subsidiary of Holdings, or by a Subsidiary of Symphony Dynamo to Symphony
Dynamo or to another wholly owned Subsidiary of Symphony Dynamo); provided,
however, that in any event any such Symphony Dynamo Equity Securities or Equity
Securities of such Subsidiary shall be issued subject to the Purchase Option;

     (ii) redeem, repurchase or otherwise acquire, directly or indirectly, any Symphony
Dynamo Equity Securities or the Equity Securities of any Subsidiary of Symphony Dynamo;

     (iii) create, incur, assume or permit to exist any Debt other than any Debt incurred
pursuant to the Operative Documents and the Development Budget (including payables incurred
in the ordinary course of business) (“Excepted Debt”); provided, however,
that the aggregate outstanding principal amount of all such Excepted Debt for borrowed money
shall not exceed [ * ] at any time;

     (iv) declare or pay dividends or other distributions on any Symphony Dynamo Equity
Securities other than any dividend declared from the proceeds of a sale or license of a
discontinued Program to a third party, in respect of which Symphony Dynamo shall be entitled
to pay (subject to the existence of lawfully available funds) a dividend equal
to the net amount (such net amount calculated as the gross proceeds received less
amounts required to be paid in respect of any and all corporate taxes owed by Symphony
Dynamo as a result of the receipt of such gross amounts) of such amounts received from such
third party;

     (v) enter into any transaction of merger or consolidation, or liquidate, wind up or
dissolve itself, or convey, transfer, license, lease or otherwise dispose of all, or a
material portion of, its properties, assets or business;

     (vi) other than in respect of the Programs, engage in the development of products for
any other company or engage or participate in the development of products or engage in any
other material line of business;

     (vii) other than entering into, and performing its obligations under, the Operative
Documents and participating in the Programs, engage in any action that negates or is
inconsistent with any rights of Dynavax set forth herein;

     (viii) other than as contemplated by the RRD Services Agreement and Section 6.2 of the
Amended and Restated Research and Development Agreement, hire, retain or contract for the
services of, any employees until the termination of such agreements;

     (ix) incur any financial commitments in respect of the development of the Programs
other than those set forth in the Development Plan and the Development Budget, or those
approved by the Development Committee and, if so required by the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

17

 

terms of Paragraph 11 of
the Development Committee Charter, the Symphony Dynamo Board in accordance with the
Operative Documents;

     (x) other than any transaction contemplated by the Operative Documents, enter into or
engage in any Conflict Transactions without the prior approval of a majority of the
Disinterested Directors of the Symphony Dynamo Board; or

     (xi) waive, alter, modify, amend or supplement in any manner whatsoever any material
terms and conditions of the RRD Services Agreement, the Funding Agreement, the Subscription
Agreement, or Articles 4 and 6 of the Amended and Restated Research and Development
Agreement, except in compliance with the terms of the Operative Documents.

          (d) Symphony Dynamo covenants and agrees to deliver, cause to be delivered, and provide access
thereto, to each other Party, each Symphony Fund, and such Auditors as Dynavax may designate, so
long as such Auditors shall be subject to confidentiality requirements at least as stringent as the
Confidentiality Agreement:

     (i) upon request, copies of the then current Development Plan for each quarter, on or
before March 31, June 30, September 30, and December 31 of each year;

     (ii) upon request, copies of the then current Development Budget for each quarter,
including a report setting forth in reasonable detail the projected expenditures by
Symphony Dynamo pursuant to the Development Budget, on or before March 31, June 30,
September 30, and December 31 of each year;

     (iii) prior to the close of each fiscal year, Symphony Dynamo shall cause the Manager
to seek to obtain from the Symphony Dynamo Auditors the Client Schedules to be provided to
Dynavax’s Auditors in connection with the Symphony Dynamo Auditors’ audit of Symphony
Dynamo. Within [ * ] Business Days after the close of each fiscal year, Symphony Dynamo (or
the Manager acting on its behalf) will provide Dynavax’s Auditors with the requested Client
Schedules. If the Symphony Dynamo Auditors deliver the Client Schedules after the end of
the fiscal year, Symphony Dynamo (or the Manager acting on its behalf) will provide the
completed Client Schedules to Dynavax’s Auditors within [ * ] Business Days of such receipt;

     (iv) prior to the close of each fiscal year, Dynavax’ Vice President of Finance, the
Symphony Dynamo Auditors, Dynavax’s Auditors and Symphony Dynamo (or the Manager acting on
its behalf) shall agree to a completion schedule that will include (A) the provision by
Symphony Dynamo to Dynavax of the financial information reasonably necessary for Dynavax to
consolidate and audit the financial results of Symphony Dynamo and (B) the following
financial statements, including the related notes thereto, audited and certified by the
Symphony Dynamo Auditors: (1) a balance sheet of Symphony Dynamo as of the close of such
fiscal year, (2) a statement of net income for such fiscal year, and (3) a statement of cash
flows for such fiscal year. Such audited annual financial statements shall set forth in
comparative form the figures for the previous fiscal year, all in reasonable detail,
prepared in accordance with GAAP, and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

18

 

Symphony Dynamo (or the Manager acting on its behalf)
shall, to the extent that Symphony Dynamo (or the Manager acting on its behalf), using
commercially reasonable means, can procure such an opinion, be accompanied by an opinion
thereon of the Symphony Dynamo Auditors to the effect that such financial statements present
fairly, in all material respects, the financial position of Symphony Dynamo and its results
of operations and cash flows and have been prepared in conformity with GAAP, and that the
examination of such accountants in connection with such financial statements has been made
in accordance with generally accepted auditing standards, and that such audit provides a
reasonable basis for such opinion in the circumstances;

     (v) within [ * ] Business Days following each calendar month and upon receipt from
Dynavax of its monthly invoice to Symphony Dynamo, current accrued monthly vendor expenses
and prepaid expenses: (A) the unaudited balance sheet of Symphony Dynamo for the previous
calendar month; (B) the unaudited statement of net income for such previous calendar month;
(C) the unaudited statement of cash flows for such previous calendar month; (D) the trial
balance schedule for such previous calendar month; and (E) related account reconciliations
for such previous calendar month;

     (vi) any other documents, materials or other information, including information and
documentation of internal controls and reporting as may be required by applicable law, rule
or regulation (including information prepared in support of Symphony Dynamo’s efforts
pursuant to Section 5(e)) pertaining to Holdings, the
Programs or Symphony Dynamo as Dynavax may reasonably request, including preliminary
financial information;

     (vii) within [ * ] Business Days following its receipt thereof from Symphony Dynamo’s
tax return preparer, a copy of each income tax return to be filed by Symphony Dynamo with
any foreign, federal, state or local taxing authority (including all supporting schedules
thereto);

     (viii) promptly, and in any event within [ * ] Business Days of receipt thereof, copies
of any notice to Symphony Dynamo from any federal or state Governmental Authority relating
to any order, ruling, statute or other law or regulation that would reasonably be expected
to have a Material Adverse Effect on Symphony Dynamo;

     (ix) promptly upon receipt thereof, notice of all actions, suits, investigations,
litigation and proceedings before any court or governmental department, commission, board,
bureau, agency or instrumentality, domestic or foreign, affecting Symphony Dynamo;

     (x) promptly upon receipt thereof, copies of any other notices, requests, reports,
financial statements and other information and documents received by Symphony Dynamo under
or pursuant to any other Operative Document, including, without limitation, any notices of
breach or termination of any subcontracts or licenses entered into or permitted pursuant to
the Operative Documents; and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

19

 

     (xi) with reasonable promptness, such other data and information relating to the
business, operations, affairs, financial condition, assets or properties of Symphony Dynamo
or relating to the ability of Symphony Dynamo to perform its obligations hereunder and under
the Operative Documents as from time to time may be reasonably requested by Dynavax and/or
Holdings;

provided, that neither Symphony Dynamo, nor the Manager acting on behalf of Symphony
Dynamo, shall have any liability to Dynavax for the failure to deliver financial documents or other
materials hereunder, if such failure was caused by a failure of Dynavax to provide, in a timely
manner, data required to prepare such financial documents or other materials to Symphony Dynavax in
a timely manner.

          (e) Symphony Dynamo will use commercially reasonable efforts, at its own expense (as set forth
in the Management Budget), to cooperate with Dynavax in meeting Dynavax’s government compliance,
disclosure, and financial reporting obligations, including without limitation under the
Sarbanes-Oxley Act of 2002 and any rules and regulations promulgated thereunder, and under FASB
Interpretation No. 46. Without limiting the foregoing, Symphony Dynamo further covenants, until
the expiration of the Term, that (w) the principal executive officer and the principal financial
officer of Symphony Dynamo, or persons performing similar functions, shall provide certifications
to Dynavax corresponding to those required with respect to public companies for which a class of
securities is registered under the Exchange Act (“Public Companies”) under Sections 302 and 906 of
the Sarbanes-Oxley Act of 2002; (x) Symphony Dynamo shall maintain a system of disclosure controls
and internal controls
(as defined under the Exchange Act) and conduct quarterly and annual evaluations of the
effectiveness of such controls as required under the Exchange Act for Public Companies; (y)
Symphony Dynamo shall provide to Dynavax an attestation report of the Symphony Dynamo Auditors with
respect to Symphony Dynamo management’s assessment of Symphony Dynamo’s internal controls as
required under the Exchange Act for Public Companies; and (z) Symphony Dynamo will maintain, or
cause to have maintained, such sufficient evidentiary support for management’s assessment of the
effectiveness of Symphony Dynamo’s internal controls as required for Public Companies.

          (f) Dynavax agrees to provide reasonable assistance and support for the financial operations
of Symphony Dynamo as may be reasonably requested by Symphony Dynamo from time to time during the
Term; provided that any such services shall be pursuant to a separate agreement specifying
the nature and amount of assistance and support to be provided and the reimbursement to Dynavax of
costs plus a reasonable profit in the provision of such assistance and support.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

20

 

          Section 6. Notice of Material Event. Each Party agrees that, upon it receiving
knowledge of a material event or development with respect to any of the transactions contemplated
hereby that, to the knowledge of its executive officers, is not known to the other Parties, such
Party shall notify the other Parties in writing within three (3) Business Days of the receipt of
such knowledge by any executive officer of such Party; provided, that the failure to
provide such notice shall not impair or otherwise be deemed a waiver of any rights any Party may
have arising from such material event or development and that notice under this Section 6
shall not in itself constitute notice of any breach of any of the Operative Documents.

          Section 7. Assignment; Transfers; Legend.

          (a) Assignment by Dynavax and Symphony Dynamo. Neither Dynavax nor Symphony Dynamo
may assign, delegate, transfer, sell or otherwise dispose of (collectively, “Transfer”), in whole
or in part, any or all of their rights or obligations hereunder to any Person (a “Transferee”)
without the prior written approval of each of the other Parties; provided, however,
that Dynavax, without the prior approval of each of the other Parties, acting in accordance with
Article 14 of the Amended and Restated Research and Development Agreement, may make such Transfer
to any Person which acquires all or substantially all of Dynavax’s assets or business (or assets or
business related to the Programs) or which is the surviving or resulting Person in a merger or
consolidation with Dynavax; provided, further, that in the event of any Transfer,
Dynavax or Symphony Dynamo, as applicable, shall provide written notice to the other Parties of any
such Transfer not later than thirty (30) days after such Transfer setting forth the identity and
address of the Transferee and summarizing the terms of the Transfer. In no event shall such
assignment alter the definition of “Dynavax Common Stock” except as a result of the surviving or
resulting “parent” entity in a merger being other than
Dynavax, in which case any reference to Dynavax Common Stock shall be deemed to instead
reference the common stock, if any, of the surviving or resulting entity.

          (b) Assignment and Transfers by Holdings. Prior to the expiration of the Purchase
Option, Holdings may not Transfer, in whole or in part, any or all of its Symphony Dynamo Equity
Securities or any or all of its rights or obligations hereunder to any Person (other than Dynavax)
without the prior written consent of Dynavax. In addition, any Transfer of Symphony Dynamo Equity
Securities by Holdings or any other Person to any Person other than Dynavax shall be conditioned
upon, and no effect shall be given to any such Transfer unless such transferee shall agree in
writing in form and substance satisfactory to Dynavax to be bound by all of the terms and
conditions hereunder, including the Purchase Option, as if such transferee were originally
designated as “Holdings” hereunder.

          (c) Legend. Any certificates evidencing Symphony Dynamo Equity Securities shall bear
a legend in substantially the following form:

THE SECURITIES OF SYMPHONY DYNAMO, INC., EVIDENCED HEREBY ARE SUBJECT TO AN OPTION,
HELD BY DYNAVAX, AS DESCRIBED IN A PURCHASE OPTION AGREEMENT (THE “PURCHASE
OPTION AGREEMENT”) DATED AS OF APRIL 18, 2006, BY AND AMONG DYNAVAX
TECHNOLOGIES CORPORATION, AND THE OTHER PARTIES THERETO, TO PURCHASE SUCH SECURITIES
AT A

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

21

 

PURCHASE PRICE DETERMINED PURSUANT TO SECTION 2 OF THE PURCHASE OPTION
AGREEMENT, EXERCISABLE BY WRITTEN NOTICE AT ANY TIME DURING THE PERIOD SET FORTH
THEREIN. COPIES OF THE PURCHASE OPTION AGREEMENT ARE AVAILABLE AT THE PRINCIPAL
PLACE OF BUSINESS OF SYMPHONY DYNAMO, INC. AT 7361 CALHOUN PLACE, SUITE 325,
ROCKVILLE, MARYLAND 20855, AND WILL BE FURNISHED TO THE HOLDER HEREOF UPON WRITTEN
REQUEST WITHOUT COST.

          Section 8. Costs and Expenses; Payments.

          (a) Symphony Dynamo Costs and Expenses. Symphony Dynamo shall pay any of its ongoing
legal expenses with respect to the transactions described in the Operative Documents from the funds
allocated for such purpose in the Management Budget.

          (b) Costs and Expenses of the Purchase Option. Except as otherwise specified in
Section 2(g) hereof, each Party shall pay its own costs and expenses incurred in connection
with the exercise of the Purchase Option.

          (c) Payments to Holdings. Payment of the Purchase Price, plus any costs and expenses
payable by Symphony Dynamo under Section 2(g) hereof, shall be made to the account of
Holdings contemporaneously with or prior to the payout of the Purchase Price on the Purchase Option
Closing Date no later than 1:00 pm (New York time).

          Section 9. Expiration; Termination of Agreement

          (a) Unexercised Expiration or Termination. If the Purchase Option granted hereunder
shall terminate or expire unexercised, and the Program Option shall have previously been exercised,
then Dynavax shall make a cash payment to Holdings in an amount equal to [ * ] in accordance with
Section 11.1(c) of the Amended and Restated Research Agreement.

          (b) Termination.

     (i) This Agreement shall terminate upon the mutual written consent of all of the
Parties.

     (ii) Subject to Section 1(c)(iv) hereof, each of Holdings and Symphony Dynamo
may terminate this Agreement in the event that Symphony Dynamo terminates the
Amended and Restated Research and Development Agreement in accordance with its terms.

          Section 10. Survival; Indemnification.

          (a) Survival of Representations and Warranties; Expiration of Certain Covenants.

     (i) The representations and warranties of the Parties contained in this Agreement shall
survive for a period of one year from the making of such representations. The liability of
the Parties related to their respective representations and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

22

 

warranties hereunder shall not
be reduced by any investigation made at any time by or on behalf of Holdings, Symphony
Dynamo or Dynavax, as applicable.

     (ii) For the avoidance of doubt, the covenants and agreements set forth in Sections
4(b), 5(b)(i), 5(b)(v)-(ix), 5(b)(xi)-(xiv),
5(c), 5(d)(i), 5(d)(ii) and 5(d)(viii)-(xi) shall,
upon the expiration of the Term, expire and end without any further obligation by Symphony
Dynamo or Holdings thereunder.

     (iii) For the avoidance of doubt, the covenants and agreements set forth in
Sections 5(b)(ii)-(iii), 5(b)(x), 5(d)(iii)-(v),
5(d)(vii), and 5(e) shall, upon the completion of all the reporting,
accounting and other obligations set forth therein with respect to the fiscal year in which
this Agreement shall terminate, expire and end without any further obligation by Symphony
Dynamo or Holdings thereunder.

          (b) Indemnification. To the greatest extent permitted by applicable law, Dynavax
shall indemnify and hold harmless Holdings and Symphony Dynamo and Holdings shall indemnify and
hold harmless Dynavax, and each of their respective Affiliates, officers, directors, employees,
agents, partners, members, successors, assigns, representatives of, and each Person, if any
(including any officers, directors, employees, agents, partners, members of such Person) who
controls Holdings, Symphony Dynamo and Dynavax, as applicable, within the meaning of the Securities
Act or the Exchange Act, (each, an “Indemnified Party”), from and against any and all actions,
causes of action, suits, claims, losses, costs, interest, penalties, fees, liabilities
and damages, and expenses in connection therewith (irrespective of whether any such
Indemnified Party is a party to the action for which indemnification hereunder is sought), and
including reasonable attorneys’ fees and disbursements (hereinafter, a “Loss”), incurred by any
Indemnified Party as a result of, or arising out of, or relating to: (i) in the case of Dynavax
being the Indemnifying Party, (A) any breach of any representation or warranty made by Dynavax
herein or in any certificate, instrument or document delivered in connection and contemporaneously
herewith, or (B) any breach of any covenant, agreement or obligation of Dynavax contained herein or
in any certificate, instrument or document delivered hereunder, and (ii) in the case of Holdings
being the Indemnifying Party, (A) any breach of any representation or warranty made by Holdings or
Symphony Dynamo herein or in any certificate, instrument or document delivered in connection and
contemporaneously herewith, or (B) any breach of any covenant, agreement or obligation of Holdings
or Symphony Dynamo contained herein or in any certificate, instrument or document delivered
hereunder. To the extent that the foregoing undertaking by Dynavax or Holdings may be
unenforceable for any reason, such Party shall make the maximum contribution to the payment and
satisfaction of any Loss that is permissible under applicable law.

          (c) Notice of Claims. Any Indemnified Party that proposes to assert a right to be
indemnified under this Section 10 shall notify Dynavax or Holdings, as applicable (the
“Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit or
proceeding against such Indemnified Party (an “Indemnified Proceeding”) in respect of which a claim
is to be made under this Section 10, or the incurrence or realization of any Loss in
respect of which a claim is to be made under this Section 10, of the commencement of such
Indemnified Proceeding or of such incurrence or realization, enclosing a copy of all relevant
documents, including all papers served and claims made, but the omission to so notify the
applicable

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

23

 

Indemnifying Party promptly of any such Indemnified Proceeding or incurrence or
realization shall not relieve (x) such Indemnifying Party from any liability that it may have to
such Indemnified Party under this Section 10 or otherwise, except, as to such Indemnifying
Party’s liability under this Section 10, to the extent, but only to the extent, that such
Indemnifying Party shall have been prejudiced by such omission, or (y) any other indemnitor from
liability that it may have to any Indemnified Party under the Operative Documents.

          (d) Defense of Proceedings. In case any Indemnified Proceeding shall be brought
against any Indemnified Party, it shall notify the applicable Indemnifying Party of the
commencement thereof as provided in Section 10(c), and such Indemnifying Party shall be
entitled to participate in, and provided such Indemnified Proceeding involves a claim solely for
money damages and does not seek an injunction or other equitable relief against the Indemnified
Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified
Proceeding with counsel reasonably satisfactory to such Indemnified Party. After notice from such
Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election so to assume the
defense thereof and the failure by such Indemnified Party to object to such counsel within ten (10)
Business Days following its receipt of such notice, such Indemnifying Party shall not be liable to
such Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred
after such notice of election to assume such defense except as provided below and except for the
reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred
by such Indemnified Party reasonably necessary in connection with the defense thereof. Such
Indemnified Party shall have the right to employ its counsel in
any such Indemnified Proceeding, but the reasonable fees and expenses of such counsel shall be
at the expense of such Indemnified Party unless:

     (i) the employment of counsel by such Indemnified Party at the expense of the
applicable Indemnifying Party has been authorized in writing by such Indemnifying Party;

     (ii) such Indemnified Party shall have reasonably concluded in its good faith (which
conclusion shall be determinative unless a court determines that such conclusion was not
reached reasonably and in good faith) that there is or may be a conflict of interest between
the applicable Indemnifying Party and such Indemnified Party in the conduct of the defense
of such Indemnified Proceeding or that there are or may be one or more different or
additional defenses, claims, counterclaims, or causes of action available to such
Indemnified Party (it being agreed that in any case referred to in this clause (ii) such
Indemnifying Party shall not have the right to direct the defense of such Indemnified
Proceeding on behalf of the Indemnified Party);

     (iii) the applicable Indemnifying Party shall not have employed counsel reasonably
acceptable to the Indemnified Party, to assume the defense of such Indemnified Proceeding
within a reasonable time after notice of the commencement thereof (provided,
however, that this clause (iii) shall not be deemed to constitute a waiver of any
conflict of interest that may arise with respect to any such counsel); or

     (iv) any counsel employed by the applicable Indemnifying Party shall fail to timely
commence or diligently conduct the defense of such Indemnified Proceeding and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

24

 

such failure
has materially prejudiced (or, in the reasonable judgment of the Indemnified Party, is in
danger of materially prejudicing) the outcome of such Indemnified Proceeding;

in each of which cases the reasonable fees and expenses of counsel for such Indemnified Party shall
be at the expense of such Indemnifying Party. Only one counsel shall be retained by all
Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any Indemnified
Party reasonably concludes in good faith (which conclusion shall be determinative unless a court
determines that such conclusion was not reached reasonably and in good faith) that there is or may
be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties
in the conduct of the defense of such Indemnified Proceeding or that there are or may be one or
more different or additional defenses, claims, counterclaims, or causes or action available to such
Indemnified Party.

          (e) Settlement. Without the prior written consent of such Indemnified Party, such
Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any
pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or
related judgment (i) includes an unconditional release of such Indemnified Party from all liability
for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii)
provides for the payment of money damages as the sole relief for the claimant (whether at law or in
equity), (iii) involves no finding or admission of any violation of law or the rights of any Person
by the Indemnified Party, and (iv) is not in the nature of a criminal or regulatory
action. No Indemnified Party shall settle or compromise, or consent to the entry of any
judgment in, any pending or threatened Indemnified Proceeding in respect of which any payment would
result hereunder or under the Operative Documents without the prior written consent of the
Indemnifying Party, such consent not to be unreasonably conditioned, withheld or delayed.

          Section 11. No Petition. Each of Dynavax and Holdings covenants and agrees that,
prior to the date which is one year and one day after the expiration of the Purchase Option Period,
it will not institute or join in the institution of any bankruptcy, insolvency, reorganization or
similar proceeding against Symphony Dynamo. The provisions of this Section 11 shall
survive the termination of this Agreement.

          Section 12. Third-Party Beneficiary. Each of the Parties agrees that each Symphony
Fund shall be a third-party beneficiary of this Agreement.

          Section 13. Notices. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any Party shall be in writing and shall
be deemed given only if delivered to the Party personally or sent to the Party by facsimile
transmission (promptly followed by a hard-copy delivered in accordance with this Section
13), by next Business Day delivery by a nationally recognized courier service, or by registered
or certified mail (return receipt requested), with postage and registration or certification fees
thereon prepaid, addressed to the Party at its address set forth below:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

25

 

Dynavax:

Dynavax Technologies Corporation

2929 Seventh Street, Suite 100

Berkeley, CA 94710

Attn: Deborah Smeltzer, VP, Operations & CFO

Facsimile: (510) 848-1327

Symphony Dynamo:

Symphony Dynamo, Inc.

7361 Calhoun Place, Suite 325

Rockville, MD 20850

Attn: Charles W. Finn, Ph.D.

Facsimile: (301) 762-6154

Holdings:

Symphony Dynamo Holdings LLC

7361 Calhoun Place, Suite 325

Rockville, MD 20850

Attn: Joseph P. Clancy

Facsimile: (301) 762-6154

   with copies to:

Symphony Capital Partners, L.P.

875 Third Avenue

18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

   and

Symphony Strategic Partners, LLC

875 Third Avenue

18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

or to such other address as such Party may from time to time specify by notice given in the manner
provided herein to each other Party entitled to receive notice hereunder.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

26

 

          Section 14. Governing Law; Consent to Jurisdiction and Service of Process.

          (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of New York; except to the extent that this Agreement pertains to the internal governance of
Symphony Dynamo or Holdings, and to such extent this Agreement shall be governed and construed in
accordance with the laws of the State of Delaware.

          (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of any New York State court and Delaware State court or
federal court of the United States of America sitting in The City of New York, Borough of Manhattan
or Wilmington, Delaware, and any appellate court from any jurisdiction thereof, in any action or
proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any
judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in
respect of any such action or proceeding may be heard and determined in any such New York State
court, any such Delaware State court or, to the fullest extent permitted by law, in such federal
court. Each of the Parties agrees that a final
judgment in any such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this
Agreement shall affect any right that any Party may otherwise have to bring any action or
proceeding relating to this Agreement.

          (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any New
York State or federal court, or any Delaware State or federal court. Each of the Parties hereby
irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to
the maintenance of such action or proceeding in any such court. Each of the parties hereby
consents to service of process by mail.

          SECTION 15. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL
RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT
OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT.

          Section 16. Entire Agreement. This Agreement (including any Annexes, Schedules,
Exhibits or other attachments hereto) constitutes the entire agreement between the Parties with
respect to the matters covered hereby and supersedes all prior agreements and understanding with
respect to such matters between the Parties.

          Section 17. Amendment; Successors; Counterparts.

          (a) The terms of this Agreement shall not be altered, modified, amended, waived or
supplemented in any manner whatsoever except by a written instrument signed by each of the Parties.

          (b) Except as set forth in Section 12, nothing expressed or implied herein is intended
or shall be construed to confer upon or to give to any Person, other than the Parties, any

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

27

 

right,
remedy or claim under or by reason of this Agreement or of any term, covenant or condition hereof,
and all the terms, covenants, conditions, promises and agreements contained herein shall be for the
sole and exclusive benefit of the Parties and their successors and permitted assigns.

          (c) This Agreement may be executed in one or more counterparts, each of which, when executed,
shall be deemed an original but all of which, taken together, shall constitute one and the same
Agreement.

          Section 18. Specific Performance. The Parties acknowledge that irreparable damage
would result if this Agreement were not specifically enforced, and they therefore agree that the
rights and obligations of the Parties under this Agreement may be enforced by a decree of specific
performance issued by a court of competent jurisdiction. Such a remedy shall, however, not be
exclusive, and shall be in addition to any other remedies which any Party may have under this
Agreement or otherwise. The Parties further acknowledge and agree that a decree of specific
performance may not be an available remedy in all circumstances.

          Section 19. Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of law or public policy, all other conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not affected in a manner
materially adverse to either party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible
in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.

          Section 20. Tax Reporting . The Parties acknowledge and agree that, for all
federal and state income tax purposes:

          (a) (i) Holdings shall be treated as the owner of all the Equity Securities of Symphony
Dynamo; (ii) the Purchase Option shall be treated as an option to acquire all the Equity Securities
of Symphony Dynamo; (iii) the Warrant shall be treated as option premium payable in respect of the
grant of the Purchase Option; and (iv) Symphony Dynamo shall be treated as the owner of all the
Licensed Intellectual Property and shall be entitled to all deductions claimed under Section 174 of
the Code in respect of the Licensed Intellectual Property to the extent of the amounts funded by
Symphony Dynamo; and

          (b) no Party shall take any tax position inconsistent with any position described in Section
20(a) above, except (i) in the event of a “determination” (as defined in Section 1313 of
the Code) to the contrary, or (ii) in the event either of the Parties receives an opinion of
counsel to the effect that there is no reasonable basis in law for such a position or that a tax
return cannot be prepared based on such a position without being subject to substantial
understatement penalties; provided, however, that in the case of Dynavax, such
counsel shall be reasonably satisfactory to Holdings.

{SIGNATURES FOLLOW ON NEXT PAGE}

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

28

 

          IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the day and year first
above written.

	 	 	 	 	 
	 	DYNAVAX TECHNOLOGIES CORPORATION

 	 
	 	By:  	/s/ Dino Dina
 	 
	 	 	Name:  	Dino Dina, M.D. 	 
	 	 	Title:  	President & Chief Executive Officer 	 
	 
	 	SYMPHONY DYNAMO HOLDINGS LLC

 	 
	 	By:  	Symphony Capital Partners, L.P.,
 	 
	 	 	its Manager 	 
	 	 	 
	 	By:  	Symphony Capital GP, L.P.,
 	 
	 	 	its general partner 	 
	 	 	 
	 	By:  	 Symphony GP, LLC,
 	 
	 	 	its general partner 	 
	 	 	 
	 	By:  	                     /s/ Mark Kessel
 	 
	 	 	Name:  	Mark Kessel 	 
	 	 	Title:  	Managing Member 	 
	 
	 	SYMPHONY DYNAMO, INC.

 	 
	 	By:  	/s/ Harri V. Taranto
 	 
	 	 	Name:  	Harri V. Taranto 	 
	 	 	Title:  	Chairman of the Board 	 
	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Purchase Option Agreement

 

 

SCHEDULE I

PURCHASE PRICE TABLE

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

ANNEX A

CERTAIN DEFINITIONS

          “$” means United States dollars.

          “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D promulgated
under the Securities Act of 1933, as amended.

          “Act” means the Delaware Limited Liability Company Act, 6 Del. C. § 18-101 et seq.

          “Ad Hoc Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended and
Restated Research and Development Agreement.

          “Additional Funds” has the meaning set forth in Section 2(b) of the Funding Agreement.

          “Additional Funding Date” has the meaning set forth in Section 3 of the Funding Agreement.

          “Additional Party” has the meaning set forth in Section 13 of the Confidentiality Agreement.

          “Additional Regulatory Filings” means such Governmental Approvals as required to be made under
any law applicable to the purchase of the Symphony Dynamo Equity Securities under the Purchase
Option Agreement.

          “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Affected Member” has the meaning set forth in Section 27 of the Investors LLC Agreement.

          “Affiliate” means, with respect to any Person (i) any Person directly or indirectly
controlling, controlled by or under common control with such Person, (ii) any officer, director,
general partner, member or trustee of such Person, or (iii) any Person who is an officer, director,
general partner, member or trustee of any Person described in clauses (i) or (ii) of this sentence.
For purposes of this definition, the terms “controlling,” “controlled by” or “under common control
with” shall mean the possession, direct or indirect, of the power to direct or cause the direction
of the management and policies of a Person or entity, whether through the ownership of voting
securities, by contract or otherwise, or the power to elect at least 50% of the directors,
managers, general partners, or persons exercising similar authority with respect to such Person or
entities.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Amended and Restated Research and Development Agreement” means the Amended and Restated
Research and Development Agreement dated as of the Closing Date, among Dynavax, Holdings and
Symphony Dynamo.

          “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Auditors” means an independent certified public accounting firm of recognized national
standing.

          [ * ]

          “Bankruptcy Code” means the United States Bankruptcy Code.

          “Berna” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and
Development Agreement.

          “Business Day” means any day other than Saturday, Sunday or any other day on which commercial
banks in The City of New York or the City of San Francisco are authorized or required by law to
remain closed.

          “Cancer Products” mean [ * ].

          “Cancer Program” means the identification, development, manufacture and/or use of any Cancer
Products in accordance with the Development Plan.

          “Capital Contributions” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Capitalized Leases” means all leases that have been or should be, in accordance with GAAP,
recorded as capitalized leases.

          “Cash Available for Distribution” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and Restated
Research and Development Agreement.

          “Change of Control” means and includes the occurrence of any of the following events, but
specifically excludes (i) acquisitions of capital stock directly from Dynavax for cash, whether in
a public or private offering, (ii) sales of capital stock by stockholders of Dynavax, and (iii)
acquisitions of capital stock by or from any employee benefit plan or related trust:

     (a) the merger, reorganization or consolidation of Dynavax into or with another
corporation or legal entity in which Dynavax’s stockholders holding the right to vote with
respect to matters generally immediately preceding such merger, reorganization or
consolidation, own less than fifty percent (50%) of the voting securities of the surviving
entity; or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

     (b) the sale of all or substantially all of Dynavax’s assets or business.

          “Class A Member” means a holder of a Class A Membership Interest.

          “Class A Membership Interest” means a Class A Membership Interest in Holdings.

          “Class B Member” means a holder of a Class B Membership Interest.

          “Class B Membership Interest” means a Class B Membership Interest in Holdings.

          “Class C Member” means a holder of a Class C Membership Interest.

          “Class C Membership Interest” means a Class C Membership Interest in Holdings.

          “Closing Certificate for Section 5.1(e)” means the written certificate, pertaining to the
representations made by Dynavax under Section 5.1(e) of the Novated and Restated Technology License
Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing
Date.

          “Closing Certificate for Section 5.1(f)” means the written certificate, pertaining to the
representations made by Dynavax under Section 5.1(f) of the Novated and Restated Technology License
Agreement, provided by Dynavax to Symphony Dynamo Holdings LLC and Symphony Dynamo on the Closing
Date.

          “Client Schedules” has the meaning set forth in Section 5(b)(i) of the RRD Services Agreement.

          “Clinical Budget Component” has the meaning set forth in Section 4.1 of the Amended and
Restated Research and Development Agreement.

          “Closing Date” means April 18, 2006.

          “CMC” means the chemistry, manufacturing and controls documentation as required for filings
with Regulatory Authority relating to the manufacturing, production and testing of drug products.

          “Code” means the Internal Revenue Code of 1986, as amended from time to time.

          “Committed Capital” means $50,000,000.00.

          “Common Stock” means the common stock, par value $0.01 per share, of Symphony Dynamo.

          “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings LLC Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Company Property” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Confidential Information” has the meaning set forth in Section 2 of the Confidentiality
Agreement.

          “Confidentiality Agreement” means the Confidentiality Agreement, dated as of the Closing Date,
among Symphony Dynamo, Holdings, Dynavax, each Symphony Fund, SCP, SSP, Investors, Symphony
Capital, RRD and Ann M. Arvin, M.D.

          “Conflict Transaction” has the meaning set forth in Article X of the Symphony 
Dynamo Charter.

          “Control” means, with respect to any material, information or intellectual property right,
that a Party owns or has a license to such item or right, and has the ability to grant the other
Party access, a license or a sublicense (as applicable) in or to such item or right as provided in
the Operative Documents without violating the terms of any agreement or other arrangement with any
third party.

          “Debt” of any Person means, without duplication:

     (a) all indebtedness of such Person for borrowed money,

     (b) all obligations of such Person for the deferred purchase price of property or
services (other than any portion of any trade payable obligation that shall not have
remained unpaid for 91 days or more from the later of (A) the original due date of such
portion and (B) the customary payment date in the industry and relevant market for such
portion),

     (c) all obligations of such Person evidenced by bonds, notes, debentures or other
similar instruments,

     (d) all obligations of such Person created or arising under any conditional sale or
other title retention agreement with respect to property acquired by such Person (whether or
not the rights and remedies of the seller or lender under such agreement in an event of
default are limited to repossession or sale of such property),

     (e) all Capitalized Leases to which such Person is a party,

     (f) all obligations, contingent or otherwise, of such Person under acceptance, letter
of credit or similar facilities,

     (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise
acquire for value any Equity Securities of such Person,

     (h) the net amount of all financial obligations of such Person in respect of Hedge
Agreements,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

     (i) the net amount of all other financial obligations of such Person under any contract
or other agreement to which such Person is a party,

     (j) all Debt of other Persons of the type described in clauses (a) through (i) above
guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed,
directly or indirectly, by such Person through an agreement (A) to pay or purchase such Debt
or to advance or supply funds for the payment or purchase of such Debt, (B) to purchase,
sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for
the purpose of enabling the debtor to make payment of such Debt or to assure the holder of
such Debt against loss, (C) to supply funds to or in any other manner invest in the debtor
(including any agreement to pay for property or services irrespective of whether such
property is received or such services are rendered) or (D) otherwise to assure a creditor
against loss, and

     (k) all Debt of the type described in clauses (a) through (i) above secured by (or for
which the holder of such Debt has an existing right, contingent or otherwise, to be secured
by) any Encumbrance on property (including accounts and contract rights) owned or held or
used under lease or license by such Person, even though such Person has not assumed or
become liable for payment of such Debt.

          “Development Budget” means the budget (comprised of the Management Budget Component and the
Clinical Budget Component) for the implementation of the Development Plan (the initial form of
which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the
Amended and Restated Research and Development Agreement as Annex D thereto), as may be further
developed and revised from time to time in accordance with the Development Committee Charter and
the Amended and Restated Research and Development Agreement.

          “Development Committee” has the meaning set forth in Article 3 of the Amended and Restated
Research and Development Agreement.

          “Development Committee Charter” has the meaning set forth in Article 3 of the Amended and
Restated Research and Development Agreement.

          “Development Committee Member” has the meaning set forth in Paragraph 1 of Annex B to the
Amended and Restated Research and Development Agreement.

          “Development Plan” means the development plan covering all the Programs (the initial form of
which was agreed upon by Dynavax and Symphony Dynamo as of the Closing Date and attached to the
Amended and Restated Research and Development Agreement as Annex C thereto), as may be further
developed and revised from time to time in accordance with the Development Committee Charter and
the Amended and Restated Research and Development Agreement.

          “Development Services” has the meaning set forth in Section 1(b) of the RRD Services
Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Director(s)” has the meaning set forth in the Preliminary Statement of the Indemnification
Agreement.

          “Disclosing Party” has the meaning set forth in Section 3 of the Confidentiality Agreement.

          “Discontinuation Closing Date” has the meaning set forth in Section 11.3 of the Amended and
Restated Research and Development Agreement.

          “Discontinuation Date” means any date designated by Symphony Dynamo which shall occur on or
after the 90th day following the receipt by Dynavax of notice from Symphony Dynamo of
Symphony Dynamo’s intent to discontinue a Program in accordance with the terms of the Amended and
Restated Research and Development Agreement.

          “Discontinuation Option” has the meaning set forth in Section 11.3 of the Amended and Restated
Research and Development Agreement.

          “Discontinuation Price” has the meaning set forth in Section 11.3 of the Amended and Restated
Research and Development Agreement.

          “Discontinuation Price Dispute Notice” has the meaning set forth in Section 11.3(b) of the
Amended and Restated Research and Development Agreement.

          “Discontinued Program” has the meaning set forth in Section 2.11 of the Novated and Restated
Technology License Agreement.

          “Discontinuation Program Funding” has the meaning set forth in Section 11.3(b) of the Amended
and Restated Research and Development Agreement.

          “Disinterested Directors” has the meaning set forth in Article X of the Symphony Dynamo
Charter.

          “Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Dynavax” means Dynavax Technologies Corporation, a Delaware corporation.

          “Dynavax Common Stock” means the common stock, par value $0.001 per share, of Dynavax.

          “Dynavax Common Stock Valuation” has the meaning set forth in Section 2(e) of the Purchase
Option Agreement.

          “Dynavax Obligations” has the meaning set forth in Section 6.1 of the Amended and Restated
Research and Development Agreement.

          “Dynavax Personnel” has the meaning set forth in Section 8.4 of the Amended and Restated
Research and Development Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Dynavax Subcontractor” has the meaning set forth in Section 6.2 of the Amended and Restated
Research and Development Agreement.

          “Early Purchase Option Exercise” has the meaning set forth in Section 1(c)(iv) of the Purchase
Option Agreement.

          “Effective Registration Date” has the meaning set forth in Section 1(b) of the Registration
Rights Agreement

          “Encumbrance” means (i) any security interest, pledge, mortgage, lien (statutory or other),
charge or option to purchase, lease or otherwise acquire any interest, (ii) any adverse claim,
restriction, covenant, title defect, hypothecation, assignment, deposit arrangement, license or
other encumbrance of any kind, preference or priority, or (iii) any other security agreement or
preferential arrangement of any kind or nature whatsoever (including, without limitation, any
conditional sale or other title retention agreement).

          “Enhancements” means findings, improvements, discoveries, inventions, additions,
modifications, enhancements, derivative works, clinical development data, or changes to the
Licensed Intellectual Property and/or Regulatory Files, in each case whether or not patentable.

          “Equity Securities” means, with respect to any Person, shares of capital stock of (or other
ownership or profit interests in) such Person, warrants, options or other rights for the purchase
or other acquisition from such Person of shares of capital stock of (or other ownership or profit
interests in) such Person, securities convertible into or exchangeable for shares of capital stock
of (or other ownership or profit interests in) such Person or warrants, rights or options for the
purchase or other acquisition from such Person of such shares (or such other interests), and other
ownership or profit interests in such Person (including, without limitation, partnership, member or
trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants,
options, rights or other interests are authorized or otherwise existing on any date of
determination.

          “ERISA” means the United States Employee Retirement Income Security Act of 1974, as amended.

          “Excepted Debt” has the meaning set forth in Section 5(c)(iii) of the Purchase Option
Agreement.

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

          “Excluded ISS” means [ * ].

          “Existing NDA” has the meaning set forth in Section 2 of the Confidentiality Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “External Directors” has the meaning set forth in the preamble of the Confidentiality
Agreement.

          “FDA” means the United States Food and Drug Administration or its successor agency in the
United States.

          “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and Restated Research
and Development Agreement.

          “Final Discontinuation Price” has the meaning set forth in Section 11.3(c) of the Amended and
Restated Research and Development Agreement.

          “Financial Audits” has the meaning set forth in Section 6.6 of the Amended and Restated
Research and Development Agreement.

          “Financing” has the meaning set forth in the Preliminary Statement of the Purchase Option
Agreement.

          “Fiscal Year” has the meaning set forth in each Operative Document in which it appears.

          “Form S-3” means the Registration Statement on Form S-3 as defined under the Securities Act.

          “FTE” has the meaning set forth in Section 4.1 of the Amended and Restated Research and
Development Agreement.

          “Funding Agreement” means the Funding Agreement, dated as of the Closing Date, among Dynavax,
SCP and Investors.

          “Funding Notice” has the meaning set forth in Section 2(b) of the Funding Agreement.

          “GAAP” means generally accepted accounting principles in effect in the United States of
America from time to time.

          “Governmental Approvals” means authorizations, consents, orders, declarations or approvals of,
or filings with, or terminations or expirations of waiting periods imposed by any Governmental
Authority.

          “Governmental Authority” means any United States or non-United States federal, national,
supranational, state, provincial, local, or similar government, governmental, regulatory or
administrative authority, agency or commission or any court, tribunal, or judicial or arbitral
body.

          “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation,
determination or award entered by or with any Governmental Authority.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Hedge Agreement” means any interest rate swap, cap or collar agreement, interest rate future
or option contract, currency swap agreement, currency future or option contract or other similar
hedging agreement.

          “Hepatitis B Products” mean [ * ].

          “Hepatitis B Program” means the identification, development, manufacture and/or use of any
Hepatitis B Products in Accordance with the Development Plan.

          “Hepatitis C Products” mean [ * ].

          “Hepatitis C Program” means the identification, development, manufacture and/or use of any
Hepatitis C Products in Accordance with the Development Plan.

          “Holdings” means Symphony Dynamo Holdings LLC, a Delaware limited liability company.

          “Holdings Claims” has the meaning set forth in Section 5.01 of the Warrant Purchase Agreement.

          “Holdings LLC Agreement” means the Amended and Restated Limited Liability Company Agreement of
Holdings, dated as of the Closing Date.

          “HSR Act Filings” means the premerger notification and report forms required under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

          “IND” means an Investigational New Drug Application, as described in 21 U.S.C. § 355(i)(1) and
21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug Administration,
or any foreign equivalent thereof.

          “Indemnification Agreement” means the Indemnification Agreement among Symphony Dynamo and the
Directors named therein, dated as of the Closing Date.

          “Indemnified Party” has the meaning set forth in each Operative Document in which it appears.

          “Indemnified Proceeding” has the meaning set forth in each Operative Document in which it
appears.

          “Indemnifying Party” has the meaning set forth in each Operative Document in which it appears.

          “Independent Accountant” has the meaning set forth in Section 11.3(c) of the Amended and
Restated Research and Development Agreement.

          “Initial Development Budget” means the initial development budget prepared by representatives
of Symphony Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated
Research and Development Agreement as Annex D thereto.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Initial Development Plan” means the initial development plan prepared by representatives of
Symphony Dynamo and Dynavax prior to the Closing Date, and attached to the Amended and Restated
Research and Development Agreement as Annex C thereto.

          “Initial Funds” has the meaning set forth in Section 2(a) of the Funding Agreement.

          “Initial Holdings LLC Agreement” means the Agreement of Limited Liability Company of Holdings,
dated January 10, 2006.

          “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of
Investors, dated January 10, 2006.

          “Initial LLC Member” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Interest Certificate” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          Investment Company Act” means the Investment Company Act of 1940, as amended.

          “Investment Overview” means the investment overview describing the transactions entered into
pursuant to the Operative Documents.

          “Investment Policy” has the meaning set forth in Section 1(a)(vi) of the RRD Services
Agreement.

          “Investors” means Symphony Dynamo Investors LLC.

          “Investors LLC Agreement” means the Amended and Restated Agreement of Limited Liability
Company of Investors dated as of the Closing Date

          “IRS” means the U.S. Internal Revenue Service.

          “ISS” means any synthetic oligonucleotide sequence or chimeric oligonucleotide sequence that
modulates an immune response, including, but not limited to, such sequences referred to by Dynavax
as immunostimulatory sequences, chimeric immunomodulatory compounds and branched immunomodulatory
compounds.

          “Knowledge” means the actual (and not imputed) knowledge of the executive officers of Dynavax,
without the duty of inquiry or investigation.

          “Law” means any law, statute, treaty, constitution, regulation, rule, ordinance, order or
Governmental Approval, or other governmental restriction, requirement or determination, of or by
any Governmental Authority.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “License” has the meaning set forth in the Preliminary Statement of the Purchase Option
Agreement.

          “Licensed Intellectual Property” means the Licensed Patent Rights, Symphony  Dynamo
Enhancements, Licensor Enhancements and the Licensed Know-How.

          “Licensed Know-How” means [ * ].

     (a) “Licensed Patent Rights” means:[ * ].

          “Licensor” means Dynavax.

          “Licensor Enhancements” means [ * ].

          “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Liquidating Event” has the meaning set forth in Section 8.01 of the Holdings LLC Agreement.

          “LLC Agreements” means the Initial Holdings LLC Agreement, the Holdings LLC Agreement, the
Initial Investors LLC Agreement and the Investors LLC Agreement.

          “Loss” has the meaning set forth in each Operative Document in which it appears.

          “Management Budget Component” has the meaning set forth in Section 4.1 of the Amended and
Restated Research and Development Agreement.

          “Management Fee” has the meaning set forth in Section 6(a) of the RRD Services Agreement.

          “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth in such
LLC Agreement, and (ii) for each other Operative Document in which it appears, RRD.

          “Management Services” has the meaning set forth in Section 1(a) of the RRD Services Agreement.

          “Manager Event” has the meaning set forth in Section 3.01(g) of the Holdings LLC Agreement.

          “Material Adverse Effect” means, with respect to any Person, a material adverse effect on (i)
the business, assets, property or condition (financial or otherwise) of such Person or, (ii) its
ability to comply with and satisfy its respective agreements and obligations under the Operative
Documents or, (iii) the enforceability of the obligations of such Person of any of the Operative
Documents to which it is a party.

          “Material Subsidiary” means, at any time, a Subsidiary of Dynavax having assets in an amount
equal to at least 5% of the amount of total consolidated assets of Dynavax and its

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Subsidiaries (determined as of the last day of the most recent reported fiscal quarter of
Dynavax) or revenues or net income in an amount equal to at least 5% of the amount of total
consolidated revenues or net income of Dynavax and its Subsidiaries for the 12-month period ending
on the last day of the most recent reported fiscal quarter of Dynavax.

          “Medical Discontinuation Event” means [ * ].

          “Membership Interest” means (i) for each LLC Agreement in which it appears, the meaning set
forth in such LLC Agreement, and (ii) for each other Operative Document in which it appears, the
meaning set forth in the Holdings LLC Agreement.

          “NASDAQ” means the National Association of Securities Dealers Automated Quotation System.

          “NDA” means a New Drug Application, as defined in the regulations promulgated by the United
States Food and Drug Administration, or any foreign equivalent thereof.

          “Non-Dynavax Capital Transaction” means any (i) sale or other disposition of all or part of
the Symphony Dynamo Shares or all or substantially all of the operating assets of Symphony Dynamo,
to a Person other than Dynavax or an Affiliate of Dynavax or (ii) distribution in kind of the
Symphony Dynamo Shares following the expiration of the Purchase Option.

          “Non-Symphony Dynamo ISS” means [ * ].

          “Novated and Restated Technology License Agreement” means the Novated and Restated
Technology License Agreement, dated as of the Closing Date, among Dynavax, Symphony Dynamo and
Holdings.

          “Operative Documents” means, collectively, the Indemnification Agreement, the Holdings LLC
Agreement, the Purchase Option Agreement, the Warrant Purchase Agreement, the Registration Rights
Agreement, the Subscription Agreement, the Technology License Agreement, the Novated and Restated
Technology License Agreement, the RRD Services Agreement, the Research and Development Agreement,
the Amended and Restated Research and Development Agreement, the Confidentiality Agreement, the
Funding Agreement and each other certificate and agreement executed in connection with any of the
foregoing documents.

          “Organizational Documents” means any certificates or articles of incorporation or formation,
partnership agreements, trust instruments, bylaws or other governing documents.

          “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii) of the Purchase Option
Agreement.

          “Party(ies)” means, for each Operative Document or other agreement in which it appears, the
parties to such Operative Document or other agreement, as set forth therein. With respect to any
agreement in which a provision is included therein by reference to a provision in

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

another agreement, the term “Party” shall be read to refer to the parties to the document at
hand, not the agreement that is referenced.

          “Payment Terms” has the meaning set forth in Section 8.2 of the Amended and Restated Research
and Development Agreement.

          “Percentage” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Permitted Investments” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Permitted Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Person” means any individual, partnership (whether general or limited), limited liability
company, corporation, trust, estate, association, nominee or other entity.

          “Personnel” of a Party means such Party, its employees, subcontractors, consultants,
representatives and agents.

          “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or, if such bank ceases to
exist or is not quoting a base rate, prime rate reference rate or similar rate for United States
dollar loans, such other major money center commercial bank in New York City selected by the
Manager.

          “Products” means Cancer Products, Hepatitis B Products and Hepatitis C Products.

          “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “Program Option” has the meaning set forth in Section 11.1(a) of the Amended and Restated
Research and Development Agreement.

          “Program Option Closing Date” has the meaning set forth in Section 11.1(b) of the Amended and
Restated Research and Development Agreement.

          “Program Option Exercise Date” has the meaning set forth in Section 11.1(b) of the Amended and
Restated Research and Development Agreement.

          “Program Option Exercise Notice” has the meaning set forth in Section 11.1(b) of the Amended
and Restated Research and Development Agreement.

          “Program Option Period” has the meaning set forth in Section 11.1(a) of the Amended and
Restated Research and Development Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Programs” means Cancer Program, Hepatitis B Program and Hepatitis C Program.

          “Protocol” means a written protocol that meets the substantive requirements of Section 6 of
the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective May 9, 1997 and is
included within the Development Plan or later modified or added to the Development Plan pursuant to
the Amended and Restated Research and Development Agreement.

          “Public Companies” has the meaning set forth in Section 5(e) of the Purchase Option Agreement.

          “Purchase Option” has the meaning set forth in Section 1(a) of the Purchase Option Agreement.

          “Purchase Option Agreement” means this Purchase Option Agreement dated as of the Closing Date,
among Dynavax, Holdings and Symphony Dynamo.

          “Purchase Option Closing” has the meaning set forth in Section 2(a) of the Purchase Option
Agreement.

          “Purchase Option Closing Date” has the meaning set forth in Section 2(a) of the Purchase
Option Agreement.

          “Purchase Option Commencement Date” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of the Purchase
Option Agreement.

          “Purchase Option Exercise Notice” has the meaning set forth in Section 2(a) of the Purchase
Option Agreement.

          “Purchase Option Interim Date” has the meaning set forth in Section 2(b)(i) of the Purchase
Option Agreement.

          “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the Purchase Option
Agreement.

          “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase Option Agreement.

          “Put Option” has the meaning set forth in Section 2A of the Purchase Option Agreement.

          “Put Option Exercise Notice” has the meaning set forth in Section 2A of the Purchase Option
Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “QA Audits” has the meaning set forth in Section 6.5 of the Amended and Restated Research and
Development Agreement.

          “Quarterly Price” has the meaning set forth in Section 2(b)(i) of the Purchase Option
Agreement.

          “Regents” has the meaning set forth in Section 3.1 of the Novated and Restated Technology
License Agreement.

          “Regents Agreement” has the meaning set forth in Section 3.1 of the Novated and Restated
Technology License Agreement.

          “Registration Rights Agreement” means the Registration Rights Agreement dated as of the
Closing Date, between Dynavax and Holdings.

          “Registration Statement” has the meaning set forth in Section 1(b) of the Registration Rights
Agreement.

          “Regulatory Authority” means the United States Food and Drug Administration, or any successor
agency in the United States, or any health regulatory authority(ies) in any other country that is a
counterpart to the FDA and has responsibility for granting registrations or other regulatory
approval for the marketing, manufacture, storage, sale or use of drugs in such other country.

          “Regulatory Allocation” has the meaning set forth in Section 3.06 of the Holdings LLC
Agreement.

          “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory Authority
with respect to the Programs.

          “Related Oncology Products Agreement” has the meaning set forth in Section 11.4 of the Amended
and Restated Research and Development Agreement.

          “Replacement Warrant(s)” has the meaning set forth in Section 7.08 of the Warrant Purchase
Agreement.

          “Representative” of any Person means such Person’s shareholders, principals, directors,
officers, employees, members, managers and/or partners.

          “Research and Development Agreement” means the Research and Development Agreement dated as of
the Closing Date, between Dynavax and Holdings.

          “Rhein” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and
Development Agreement.

          “Rhein Sale Agreement” has the meaning set forth in Section 11.2(a) of the Amended and
Restated Research and Development Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “RRD” means RRD International, LLC, a Delaware limited liability company.

          “RRD Indemnified Party” has the meaning set forth in Section 10(a) of the RRD Services
Agreement.

          “RRD Loss” has the meaning set forth in Section 10(a) of the RRD Services Agreement.

          “RRD Parties” has the meaning set forth in Section 9(e) of the RRD Services Agreement.

          “RRD Personnel” has the meaning set forth in Section 1(a)(ii) of the RRD Services Agreement.

          “RRD Services Agreement” means the RRD Services Agreement between Symphony Dynamo and RRD,
dated as the Closing Date, 2006.

          “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings LLC Agreement.

          “Scheduled Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended and
Restated Research and Development Agreement.

          “Scientific Discontinuation Event” has the meaning set forth in Section 4.2(c) of the Amended
and Restated Research and Development Agreement.

          “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership.

          “SD Program Option” has the meaning set forth in Section 11.2(b) of the Amended and Restated
Research and Development Agreement.

          “SD Program Option Exercise Notice” has the meaning set forth in Section 11.2(b) of the
Amended and Restated Research and Development Agreement.

          “SEC” means the United States Securities and Exchange Commission.

          “Securities Act” means the Securities Act of 1933, as amended.

          “Selected ISS” means [ * ].

          “Shareholder” means any Person who owns any Symphony Dynamo Shares.

          “Solvent” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement.

          “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Stock Payment Date” has the meaning set forth in Section 2 of the Subscription Agreement.

          “Stock Purchase Price” has the meaning set forth in Section 2 of the Subscription Agreement.

          “Subcontracting Agreement” has the meaning set forth in Section 6.2 of the Amended and
Restated Research and Development Agreement.

          “Subscription Agreement” means the Subscription Agreement between Symphony Dynamo and
Holdings, dated as the Closing Date.

          “Subsidiary” of any Person means any corporation, partnership, joint venture, limited
liability company, trust or estate of which (or in which) more than 50% of (a) the issued and
outstanding capital stock having ordinary voting power to elect a majority of the board of
directors of such corporation (irrespective of whether at the time capital stock of any other class
or classes of such corporation shall or might have voting power upon the occurrence of any
contingency); (b) the interest in the capital or profits of such partnership, joint venture or
limited liability company; or (c) the beneficial interest in such trust or estate is at the time
directly or indirectly owned or controlled by such Person, by such Person and one or more of its
other Subsidiaries or by one or more of such Person’s other Subsidiaries.

          “Surviving Entity” means the surviving or resulting “parent” legal entity which is surviving
entity to Dynavax after giving effect to a Change of Control.

          “Symphony Capital” means Symphony Capital LLC, a Delaware limited liability company.

          “Symphony Dynamo” means Symphony Dynamo, Inc., a Delaware corporation.

          “Symphony Dynamo Auditors” has the meaning set forth in Section 5(b) of the RRD Services
Agreement.

          “Symphony Dynamo Board” means the board of directors of Symphony Dynamo.

          “Symphony Dynamo By-laws” means the By-laws of Symphony Dynamo, as adopted by resolution of
the Symphony Dynamo Board on the Closing Date.

          “Symphony Dynamo Charter” means the Amended and Restated Certificate of Incorporation of
Symphony Dynamo, dated as of the Closing Date.

          “Symphony Dynamo Director Event” has the meaning set forth in Section 3.01(h)(i) of the
Holdings LLC Agreement.

          “Symphony Dynamo Enhancements” means [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Symphony Dynamo Equity Securities” means the Common Stock and any other stock or shares
issued by Symphony Dynamo.

          “Symphony Dynamo Loss” has the meaning set forth in Section 10(b) of the RRD Services
Agreement.

          “Symphony Dynamo Shares” has the meaning set forth in Section 2.02 of the Holdings LLC
Agreement.

          “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware limited partnership, and
Symphony Strategic Partners, LLC, a Delaware limited liability company.

          “Tangible Materials” means [ * ].

          “Tax Amount” has the meaning set forth in Section 4.02 of the Holdings LLC Agreement.

          “Technology License Agreement” means the Technology License Agreement, dated as of the Closing
Date, between Dynavax and Holdings.

          “Term” has the meaning set forth in Section 4(b)(iii) of the Purchase Option Agreement, unless
otherwise stated in any Operative Document.

          “Territory” means the world.

          “Third Party IP” has the meaning set forth in Section 2.11 of the Novated and Restated
Technology License Agreement.

          “Third Party Licensor” means a third party from which Dynavax has received a license or
sublicense to Licensed Intellectual Property.

          “Transfer” has for each Operative Document in which it appears the meaning set forth in such
Operative Document.

          “Transferee” has, for each Operative Document in which it appears, the meaning set forth in
such Operative Document.

          “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Warrant(s)” means the “Warrant” as defined in Section 2.01 of the Warrant Purchase Agreement,
and/or any successor certificates exercisable for Warrant Shares issued by Dynavax.

          “Warrant Closing” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

          “Warrant Date” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement.

          “Warrant Purchase Agreement” means the Warrant Purchase Agreement, dated as of the Closing
Date, between Dynavax and Holdings.

          “Warrant Shares” has the meaning set forth in Section 2.01 of the Warrant Purchase Agreement.

          “Warrant Surrender Price” has the meaning set forth in Section 7.08 of the Warrant Purchase
Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

EXHIBIT 1

PURCHASE OPTION EXERCISE NOTICE

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

EXHIBIT 2

FORM OF OPINION COOLEY GODWARD LLP

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

	 	 	 	 	 
	 

	 	ATTORNEYS AT LAW
	 	Broomfield, CO
	 

	 	 
	 	720 566-4000
	 

	 	Five Palo Alto Square
	 	Reston, VA
	 

	 	3000 El Camino Real
	 	703 456-8000
	 

	 	Palo Alto, CA	 	San Diego, CA
	 

	 	94306-2155
	 	858 550-6000
	 

	 	Main 650 843-5000
	 	San Francisco, CA
	 

	 	Fax 650 849-7400
	 	415 693-2000
	 
	 	 	 	 
	 

	 	www.cooley.com	 	 

April 18, 2006

Symphony Dynamo Holdings LLC

7361 Calhoun Place, Suite 325

Rockville, MD 20850

Dear Ladies and Gentlemen:

We have acted as counsel for Dynavax Technologies Corporation, a Delaware corporation (the
“Company”), in connection with the financing of certain of the Company’s research and development
programs (the “Financing”). In connection with the Financing, the Company is entering into the
agreements listed on Schedule I hereto (collectively, the “Transaction Agreements”). We are
rendering this opinion pursuant to Section 3.02(d) of the Warrant Purchase Agreement.

In connection with this opinion, we have examined and relied upon the representations and
warranties as to factual matters contained in and made pursuant to the Transaction Agreements by
the various parties and originals, or copies certified to our satisfaction, of such records,
documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary
or appropriate to enable us to render the opinion expressed below.

As to certain factual matters, we have relied upon certificates of officers of the Company and have
not sought to independently verify such matters. Where we render an opinion “to our knowledge” or
concerning an item “known to us” or our opinion otherwise refers to our knowledge, it is based
solely upon (i) an inquiry of attorneys within this firm who have represented the Company in this
transaction, (ii) receipt of a certificate executed by an officer of the Company covering such
matters and (iii) such other investigation, if any, that we specifically set forth herein.

In rendering this opinion, we have assumed: the authenticity of all documents submitted to
us as originals; the conformity to originals of all documents submitted to us as copies; the
accuracy, completeness and authenticity of certificates of public officials; the due authorization,
execution and delivery of all documents (except the due authorization, execution and delivery by
the Company of the Transaction Agreements), where authorization, execution and delivery are
prerequisites to the effectiveness of such documents; and the genuineness and authenticity of all
signatures on original documents (except the signatures on behalf of the Company on the Transaction
Agreements). We have also assumed: that all individuals executing and delivering documents had
the legal capacity to so execute and deliver; that the Transaction Agreements are

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Symphony Dynamo Holdings LLC

Page 4

obligations binding upon the parties thereto other than the Company; that the parties to the
Transaction Agreements other than the Company have filed any required California franchise or
income tax returns and have paid any required California franchise or income taxes; and that there
are no extrinsic agreements or understandings among the parties to the Transaction Agreements or to
the Material Agreements (as defined below) that would modify or interpret the terms of any such
agreements or the respective rights or obligations of the parties thereunder.

Our opinion is expressed only with respect to the federal laws of the United States of America and
the laws of the State of California and the General Corporation Law of the State of Delaware. We
note that the parties to the Transaction Agreements have designated the laws of the State of New
York as the laws governing the Transaction Agreements. Our opinion in paragraph 6 below as to the
validity, binding effect and enforceability of the Transaction Agreements is premised upon the
result that would obtain if a California court were to apply the internal laws of the State of
California (notwithstanding the designation of the laws of the State of New York) to the
interpretation and enforcement of the Transaction Agreements. We express no opinion as to whether
the laws of any particular jurisdiction apply, and no opinion to the extent that the laws of any
jurisdiction other than those identified above are applicable to the subject matter hereof, and we
have not obtained any opinion of counsel under the laws of the State of New York.

We are not rendering any opinion as to any statute, rule, regulation, ordinance, decree or
decisional law relating to antitrust, banking, land use, environmental, pension, employee benefit,
tax, fraudulent conveyance, usury, laws governing the legality of investments for regulated
entities, regulations T, U or X of the Board of Governors of the Federal Reserve System or local
law. Furthermore, we express no opinion with respect to compliance with antifraud laws, rules or
regulations relating to securities or the offer and sale thereof; compliance with fiduciary duties
by the Company’s Board of Directors or stockholders; compliance with safe harbors for disinterested
Board of Director or stockholder approvals; compliance with state securities or blue sky laws
except as specifically set forth below; or compliance with laws that place limitations on corporate
distributions.

With regard to our opinion in paragraph 1 below, we have relied solely upon a certificate of the
Secretary of State of the State of Delaware as of a recent date.

With regard to our opinion in paragraph 3 below, with respect to the due and valid authorization of
each of the Transaction Documents, we have relied solely upon (i) a certificate of an officer of
the Company, (ii) a review of the certificate of incorporation and bylaws of the Company, (iii) a
review of the resolutions certified by an officer of the Company, (iv) and a review of the Delaware
General Corporation Law.

With regard to our opinion paragraph 4 below concerning material defaults under and any material
breaches of any agreement identified on Schedule II hereto, we have relied solely upon

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Symphony Dynamo Holdings LLC

Page 5

(i) a certificate of an officer of the Company, (ii) a list supplied to us by the Company of
material agreements to which the Company is a party, or by which it is bound, a copy of which is
attached hereto as Schedule II (the “Material Agreements”) and (iii) an examination of the Material
Agreements in the form provided to us by the Company. We have made no further investigation.
Further, with regard to our opinion in paragraph 4 below concerning Material Agreements, we express
no opinion as to (i) financial covenants or similar provisions therein requiring financial
calculations or determinations to ascertain compliance, (ii) provisions therein relating to the
occurrence of a “material adverse event” or words of similar import or (iii) any statement or
writing that may constitute parol evidence bearing on interpretation or construction.

With regard to our opinion in paragraph 7 below, we express no opinion to the extent that,
notwithstanding its current reservation of shares of Common Stock, future issuances of securities
of the Company and/or antidilution adjustments to outstanding securities of the Company may cause
the Warrant Shares or the Dynavax Common Stock to exceed the number of shares of Common Stock that
then remain authorized but unissued.

With regard to our opinion in paragraph 8 concerning exemption from registration, our opinion is
expressed only with respect to the offer and sale of the Warrant or the Warrant Shares without
regard to any offers or sales of securities occurring prior to or subsequent to the date hereof.

With regard to our opinion in paragraph 9 below, we have based our opinion, to the extent we
consider appropriate, on Rule 3a-8 under the Investment Company Act of 1940, as amended, and a
certificate of an officer of the Company as to compliance with each of the requirements necessary
to comply with Rule 3a-8. We have conducted no further investigation.

On the basis of the foregoing, in reliance thereon and with the foregoing qualifications, we are of
the opinion that:

	1.	 	The Company has been duly incorporated and is a validly existing corporation in good standing
under the laws of the State of Delaware.

	2.	 	The Company has the corporate power to execute, deliver and perform its obligations under the
Transaction Agreements.

	3.	 	Each of the Transaction Agreements has been duly and validly authorized, executed and
delivered by the Company. The offer and sale of the Warrant (as defined in the Warrant
Purchase Agreement) has been duly authorized by the Company.

	4.	 	The execution and delivery of the Transaction Agreements by the Company and the issuance of
the Warrant pursuant thereto and the Warrant Shares assuming the exercise of the Warrant on
the date hereof, will not, (a) violate any provision of the Company’s certificate of
incorporation or by-laws, (b) violate any governmental statute, rule or

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Symphony Dynamo Holdings LLC

Page 6

	 	 	regulation which in our experience is typically applicable to transactions of the nature
contemplated by the Transaction Agreements, (c) violate any order, writ, judgment,
injunction, decree, determination or award which has been entered against the Company and of
which we are aware or (d) constitute a material default under or a material breach of any
Material Agreement, in the case of clauses (c) and (d) to the extent such default or breach
would materially and adversely affect the Company.
	 
	5.	 	All consents, approvals, authorizations or orders of, and filings, registrations and
qualifications with any U.S. Federal or California regulatory authority or governmental body
required for the due execution or delivery by the Company of any Transaction Agreement and the
sale and issuance of the Warrant have been made or obtained, except (a) for the filing of a
Form D pursuant to Securities and Exchange Commission Regulation D and (b) for the filing of
the notice to be filed under California Corporations Code Section 25102.1(d).
	 
	6.	 	Each of the Transaction Agreements constitutes a valid and binding agreement of the Company,
enforceable against the Company in accordance with its respective terms, except as rights to
indemnity and contribution under Sections 6 and 7 of the Registration Rights Agreement,
Section 10 of the Purchase Option Agreement, Article V of the Warrant Purchase Agreement,
Section 15 of the Research and Development Agreement, Section 15 of the Amended and Restated
Research and Development Agreement, Section 6 of the Technology License Agreement and Section
6 of the Novated and Restated Technology License Agreement may be limited by applicable laws
and except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization,
arrangement, suretyship, dissolution, moratorium, receivership or other similar laws affecting
creditors’ rights and the law of fraudulent transfer, and subject to state law, federal law,
or general equity principles and to limitations on availability of equitable relief, including
specific performance, regardless of whether enforcement is considered in a proceeding in
equity or at law.
	 
	7.	 	The Warrant Shares (as defined in the Warrant Purchase Agreement) and, the Dynavax Common
Stock (as defined in the Purchase Option Agreement), when sold and issued in accordance with
the terms of the Warrant or the Purchase Option Agreement, as applicable, will be validly
issued, fully paid and non-assessable, and the issuance of the Warrant Shares is not be
subject to preemptive rights pursuant to the General Corporation Law of the State of Delaware,
the certificate of incorporation or by-laws of the Company or similar rights to subscribe
pursuant to any Material Agreement.
	 
	8.	 	The offer and sale of the Warrant and Warrant Shares (assuming exercise of the Warrant on the
date hereof) are exempt from the registration requirements of the Securities Act of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Symphony Dynamo Holdings LLC

Page 7

	 	 	1933, as amended, subject to the timely filing of a Form D pursuant to Securities and
Exchange Commission Regulation D.
	 
	9.	 	The Company is not an “investment company” as defined in the Investment Company Act of 1940,
as amended.

[ * ]

This opinion is intended solely for your benefit and is not to be made available to or be relied
upon by any other person, firm, or entity without our prior written consent.

Very truly yours,

Cooley Godward LLP

	 	 	 	 	 
	By:

	 	/s/ Robert L. Jones	 	 
	 

	 	 	 	 
	 

	 	Robert L. Jones
	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Schedule I

List of Transaction Agreements

	i.	 	Warrant Purchase Agreement, dated as of April 18, 2006 between the Company and Symphony
Dynamo Holdings LLC (the “Warrant Purchase Agreement”).
	 
	ii.	 	Warrant to purchase 2,000,000 shares of common stock of the Company,
dated as of April 18, 2006 (the “Warrant”).

	 
	iii.	 	 Purchase Option Agreement, dated as of April 18, 2006, among the
Company, Symphony Dynamo Holdings LLC and Symphony Dynamo, Inc. (the
“Purchase Option Agreement”).
	 
	iv.	 	 Research and
Development Agreement, dated as of April 18, 2006, between the
Company and Symphony Dynamo Holdings LLC (the “Research and
Development Agreement”).
	 
	v.	 	Amended & Restated Research and Development Agreement, dated as
of April 18, 2006 among the Company, Symphony Dynamo, Inc. and
Symphony Dynamo Holdings LLC (the “Amended & Restated Research and
Development Agreement”).
	 
	vi.	 	 Technology License
Agreement, dated as of April 18, 2006 between the Company and
Symphony Dynamo Holdings LLC (the “Technology License Agreement”).
vii. Novated and Restated Technology License Agreement, dated as of April
18, 2006, among the Company, Symphony Dynamo, Inc. and Symphony
Dynamo Holdings LLC (the “Novated and Restated Technology License
Agreement”).
	 
	viii.	 	 Confidentiality Agreement, dated as of April 18, 2006, among the
Company, Symphony Dynamo, Inc., Symphony Dynamo Holdings LLC,
Symphony Capital Partners, L.P., Symphony Strategic Partners, LLC,
Symphony Dynamo Investors LLC, Symphony Capital LLC, RRD
International, LLC, and Ann M. Arvin, M.D. (the “Confidentiality
Agreement”).
	 
	ix.	 	Funding Agreement, dated as of April 18, 2006, among the Company,
Symphony Capital Partners, L.P., Symphony Dynamo Holdings LLC and
Symphony Dynamo Investors, LLC (the “Funding Agreement”).
	 
	x.	 	Registration Rights Agreement, dated as of April 18, 2006, between the Company and Symphony
Dynamo Holdings LLC (the “Registration Rights Agreement”).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

 

Schedule II

List of Material Agreements

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]